<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEXIVAÂ - fosamprenavir calciumÂ tablet, film coatedÂ </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LEXIVA safely and effectively. See full prescribing information for LEXIVA.<br>LEXIVA (fosamprenavir calcium) Tablets and Oral Suspension<br>Initial U.S. Approval: 2003</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration, Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (2.3) 4/2009 </p>
<p class="Highlighta">Warnings and Precautions (5.8) 9/2009 </p>
<p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span> (5.11) 9/2009 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">LEXIVA is an HIV protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (1)  (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul>
<li>Therapy-Naive Adults: LEXIVA 1,400Â mg twice daily; LEXIVA 1,400Â mg once daily plus ritonavir 200Â mg once daily; LEXIVA 1,400Â mg once daily plus ritonavir 100Â mg once daily; LEXIVA 700Â mg twice daily plus ritonavir 100Â mg twice daily. (2.1)</li>
<li>Protease Inhibitor-Experienced Adults: LEXIVA 700Â mg twice daily plus ritonavir 100Â mg twice daily. (2.1)</li>
<li>Pediatric Patients (2 to 18Â years of age): Dosage should be calculated based on body weight (kg) and should not exceed adult dose. (2.2)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Recommended adjustments for patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (2.3)</li>
</ul>
<p class="Highlighta">Dosing Considerations  (<a href="#section-2">2</a>)</p>
<ul>
<li>LEXIVA Tablets may be taken with or without food. (2)</li>
<li>LEXIVA Suspension: Adults should take without food; pediatric patients should take with food. (2)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">700 mg tablets and 50 mg/mL oral suspension (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to LEXIVA or amprenavir (e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>). (4)</li>
<li>Drugs highly dependent on CYP3A4 for clearance and for which elevated plasma levels may result in serious and/or life-threatening events. (4)</li>
<li>Review ritonavir contraindications when used in combination. (4)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Certain drugs should not be coadministered with LEXIVA due to risk of serious or life-threatening adverse reactions. (5.1)</li>
<li>LEXIVA should be discontinued for severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. (5.2) LEXIVA should be used with caution in patients with a known <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">sulfonamide allergy</span>. (5.3)</li>
<li>Use of higher than approved doses may lead to transaminase elevations. Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C are at increased risk of transaminase elevations. (5.4)</li>
<li>Patients receiving LEXIVA may develop new onset or exacerbations of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (5.5), <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span> (5.6), redistribution/accumulation of body fat (5.7), and elevated triglyceride and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentrations (5.8). Monitor <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides prior to therapy and periodically thereafter.</li>
<li><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Acute hemolytic anemia</span> has been reported with amprenavir. (5.9)</li>
<li><span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span>: Spontaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may occur, and additional factor VIII may be required. (5.10)</li>
<li><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span>: Cases of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> have been reported with fosamprenavir. (5.11)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>In adults the most common adverse reactions (incidence â‰¥4%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (6.1)</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> was more frequent in pediatrics than in adults. (6.1)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact <span class="Bold">GlaxoSmithKline at 1-888-825-5249 </span>or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Coadministration of LEXIVA with drugs that induce CYP3A4 may decrease amprenavir (active metabolite) concentrations leading to potential loss of virologic activity. (7, 12.3)</li>
<li>Coadministration with drugs that inhibit CYP3A4 may increase amprenavir concentrations. (7, 12.3)</li>
<li>Coadministration of LEXIVA and ritonavir may result in clinically significant interactions with drugs metabolized by CYP2D6. (7)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.2" class="toc"></a></h2>
<h2><a href="#section-2.3" class="toc"></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.2 </span> Pediatric Patients (2 to 18Â years of age)</a></h2>
<h2><a href="#section-2.5" class="toc"></a></h2>
<h2><a href="#section-2.6" class="toc"></a></h2>
<h2><a href="#section-2.7" class="toc"></a></h2>
<h2><a href="#section-2.8" class="toc"></a></h2>
<h2><a href="#section-2.9" class="toc">2.3 Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1</span> Drug Interactions</a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2</span> <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3</span> Sulfa <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4</span> Hepatic Toxicity</a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>/<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6</span> <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7</span> Fat Redistribution</a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8</span> Lipid Elevations</a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9</span> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic Anemia</span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.10</span> Patients With <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span></a></h2>
<h2><a href="#section-5.11" class="toc"><span class="Bold">5.11</span> <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span></a></h2>
<h2><a href="#section-5.12" class="toc"><span class="Bold">5.12</span> Resistance/Cross-Resistance</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP Inhibitors and Inducers</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs That Should Not Be Coadministered With LEXIVA</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Established and Other Potentially Significant Drug Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc"></a></h2>
<h2><a href="#section-11.4" class="toc"></a></h2>
<h2><a href="#section-11.5" class="toc"></a></h2>
<h2><a href="#section-11.6" class="toc"></a></h2>
<h2><a href="#section-11.7" class="toc"></a></h2>
<h2><a href="#section-11.8" class="toc"></a></h2>
<h2><a href="#section-11.9" class="toc"></a></h2>
<h2><a href="#section-11.10" class="toc"></a></h2>
<h2><a href="#section-11.11" class="toc"></a></h2>
<h2><a href="#section-11.12" class="toc"></a></h2>
<h2><a href="#section-11.13" class="toc"></a></h2>
<h2><a href="#section-11.14" class="toc"></a></h2>
<h2><a href="#section-11.15" class="toc"></a></h2>
<h2><a href="#section-11.17" class="toc"></a></h2>
<h2><a href="#section-11.18" class="toc"></a></h2>
<h2><a href="#section-11.19" class="toc"></a></h2>
<h2><a href="#section-11.20" class="toc"></a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.2" class="toc"></a></h2>
<h2><a href="#section-13.3" class="toc"></a></h2>
<h2><a href="#section-13.5" class="toc"></a></h2>
<h2><a href="#section-13.6" class="toc"><span class="Bold">14.3</span> Pediatric Patients</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc"><span class="Bold">17.1</span> Drug Interactions</a></h2>
<h2><a href="#section-15.2" class="toc"><span class="Bold">17.2</span> Sulfa <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></a></h2>
<h2><a href="#section-15.3" class="toc"><span class="Bold">17.3</span> Redistribution/Accumulation of Body Fat</a></h2>
<h2><a href="#section-15.4" class="toc"><span class="Bold">17.4</span> Information About Therapy With LEXIVA</a></h2>
<h2><a href="#section-15.5" class="toc"><span class="Bold">17.5</span> Oral Suspension</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b6930697-8feb-47c0-9db3-829826bed713"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"> LEXIVA<span class="Sup">Â®</span> is indicated in combination with other antiretroviral agents for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<p> The following points should be considered when initiating therapy with LEXIVA plus ritonavir in protease inhibitor-experienced patients:</p>
<ul>
<li>The protease inhibitor-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA plus ritonavir and lopinavir plus ritonavir are clinically equivalent <span class="Italics">[see Clinical Studies (14.2)]</span>.</li>
<li>Once-daily administration of LEXIVA plus ritonavir is not recommended for adult protease inhibitor-experienced patients or any pediatric patients.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_973b2496-69a9-4bfc-998f-6bfd96f492d2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"> LEXIVA Tablets may be taken with or without food.</p>
<p> Adults should take LEXIVA Oral Suspension without food. Pediatric patients should take LEXIVA Oral Suspension with food <span class="Italics">[see Clinical Pharmacology (12.3)].</span> If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> occurs within 30Â minutes after dosing, re-dosing of LEXIVA Oral Suspension should occur.</p>
<p> Higher-than-approved dose combinations of LEXIVA plus ritonavir are not recommended due to an increased risk of transaminase elevations <span class="Italics">[see Overdosage (10)]</span>.</p>
<p> When LEXIVA is used in combination with ritonavir, prescribers should consult the full prescribing information for ritonavir.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23a87241-f0ca-4268-8006-a6dcd87ab183"></a><a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1</span> Adults</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_493ac1e2-5242-41da-8695-a90fffeedd8a"></a><a name="section-2.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Therapy-Naive Adults</span></p>
<ul>
<li>LEXIVA 1,400Â mg twice daily (without ritonavir).</li>
<li>LEXIVA 1,400Â mg once daily plus ritonavir 200Â mg once daily.</li>
<li>LEXIVA 1,400Â mg once daily plus ritonavir 100Â mg once daily.</li>
</ul>
<p> Dosing of LEXIVA 1,400Â mg once daily plus ritonavir 100Â mg once daily is supported by pharmacokinetic data <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<ul>
<li>LEXIVA 700Â mg twice daily plus ritonavir 100Â mg twice daily.</li>
<li>Dosing of LEXIVA 700Â mg twice daily plus 100Â mg ritonavir twice daily is supported by pharmacokinetic and safety data <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a90bafa-f2c4-4ebf-954d-2986601f264f"></a><a name="section-2.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Protease Inhibitor-Experienced Adults</span></p>
<ul><li>LEXIVA 700Â mg twice daily plus ritonavir 100Â mg twice daily</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1b695d3-8de0-4cca-a283-336ab901a51b"></a><a name="section-2.4"></a><p></p>
<h2>
<span class="Bold">2.2 </span> Pediatric Patients (2 to 18Â years of age)</h2>
<p class="First"> The recommended dosage of LEXIVA in patients â‰¥2Â years of age should be calculated based on body weight (kg) and should not exceed the recommended adult dose. The data are insufficient to recommend: (1) once-daily dosing of LEXIVA alone or in combination with ritonavir, and (2) any dosing of LEXIVA in therapy-experienced patients 2 to 5Â years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3bf7c2b9-f334-407f-94a8-4d63a68e0a3f"></a><a name="section-2.5"></a><p></p>
<h2></h2>
<p class="First">Therapy-Naive 2 to 5Â Years of Age</p>
<ul><li>LEXIVA Oral Suspension 30Â mg/kg twice daily, not to exceed the adult dose of LEXIVA 1,400Â mg twice daily.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a80436e-3056-480f-80dc-963d28e3d8cd"></a><a name="section-2.6"></a><p></p>
<h2></h2>
<p class="First">Therapy-Naive â‰¥6Â Years of Age</p>
<ul><li>Either LEXIVA Oral Suspension 30Â mg/kg twice daily not to exceed the adult dose of LEXIVA 1,400Â mg twice daily or LEXIVA Oral Suspension 18Â mg/kg plus ritonavir 3Â mg/kg twice daily not to exceed the adult dose of LEXIVA 700Â mg plus ritonavir 100Â mg twice daily.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1d2f055-640e-4906-9d5b-374031194769"></a><a name="section-2.7"></a><p></p>
<h2></h2>
<p class="First">Therapy-Experienced â‰¥6Â Years of Age</p>
<ul><li>LEXIVA Oral Suspension 18Â mg/kg plus ritonavir 3Â mg/kg administered twice daily not to exceed the adult dose of LEXIVA 700Â mg twice daily plus ritonavir 100Â mg twice daily.</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ed8b159-7784-4330-bf65-2f621ae8d459"></a><a name="section-2.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Other Dosing Considerations</span></p>
<ul>
<li>When administered without ritonavir, the adult regimen of LEXIVA Tablets 1,400Â mg twice daily may be used for pediatric patients weighing at least 47Â kg. </li>
<li>When administered in combination with ritonavir, LEXIVA Tablets may be used for pediatric patients weighing at least 39Â kg; ritonavir capsules may be used for pediatric patients weighing at least 33Â kg.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b4c2a5c-8cb4-428d-97a2-3675286a091e"></a><a name="section-2.9"></a><p></p>
<h2>2.3 Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><span class="Italics">See Clinical Pharmacology (12.3)</span>.<span class="Underline">Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (Child-Pugh score ranging from 5 to 6): </span>LEXIVA should be used with caution at a reduced dosage of 700Â mg twice daily without ritonavir (therapy-naive) or 700Â mg twice daily plus ritonavir 100Â mg once daily (therapy-naive or protease inhibitor-experienced).</p>
<p><span class="Underline">Moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (Child-Pugh score ranging from 7 to 9): </span>LEXIVA should be used with caution at a reduced dosage of 700Â mg twice daily without ritonavir (therapy-naive), or 450Â mg twice daily plus ritonavir 100Â mg once daily (therapy-naive or protease inhibitor-experienced).</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline">Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (Child-Pugh score ranging from 10 to 15): </span>LEXIVA should be used with caution at a reduced dosage of 350Â mg twice daily without ritonavir (therapy-naive) or 300Â mg twice daily plus ritonavir 100Â mg once daily (therapy-naive or protease inhibitor-experienced).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_774e89bd-e812-4c63-bb2a-68a3b3420cdd"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"> LEXIVA Tablets, 700Â mg, are pink, film-coated, capsule-shaped, biconvex tablets with â€œGXÂ LL7â€? debossed on one face.</p>
<p> LEXIVA Oral Suspension, 50Â mg/mL, is a white to off-white suspension that has a characteristic grape-bubblegum-peppermint flavor.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_fc24fca1-e924-406f-814c-f23ad0af3a4a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"> LEXIVA is contraindicated: </p>
<ul>
<li>in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to any of the components of this product or to amprenavir.</li>
<li>when coadministered with drugs that are highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (Table 1).</li>
</ul>
<a name="id_c468519c-3eea-46bc-b564-534b6086a399"></a><table border="single" width="588.000">
<caption><span>Table 1. Drugs Contraindicated With LEXIVA</span></caption>
<col width="30.6%">
<col width="69.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Drug Class/Drug Name</td>
<td class="Botrule Rrule" align="center" valign="top">Clinical Comment</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Antiarrhythmics:</span></p>
Flecainide, propafenone</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">POTENTIAL</span> for serious and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> secondary to increases in plasma concentrations of antiarrhythmics if LEXIVA is co-prescribed with <span class="Bold">ritonavir</span>. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Antimycobacterials:</span></p>
Rifampin<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">May lead to loss of virologic response and possible resistance to LEXIVA or to the class of protease inhibitors.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Ergot derivatives:</span></p>
Dihydroergotamine, ergonovine, ergotamine, methylergonovine</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">POTENTIAL </span>for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">GI motility agents:</span></p>
Cisapride</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">POTENTIAL </span>for serious and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Herbal products: </span></p>
St. Johnâ€™s wort (<span class="Italics">hypericum perforatum</span>)</td>
<td class="Botrule Rrule" align="left" valign="top">May lead to loss of virologic response and possible resistance to LEXIVA or to the class of protease inhibitors.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">HMG co-reductase inhibitors:</span></p>
Lovastatin, simvastatin </td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">POTENTIAL </span>for serious reactions such as risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Neuroleptic: </span></p>
Pimozide</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">POTENTIAL</span> for serious and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span></p>
Delavirdine<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">May lead to loss of virologic response and possible resistance to delavirdine.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Sedative/hypnotics: </span></p>
Midazolam, triazolam</td>
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">POTENTIAL</span> for serious and/or life-threatening reactions such as prolonged or increased sedation or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a Â </span><span class="Italics">See Clinical Pharmacology (12.3) Tables 10, 11, 12, or 13 for magnitude of interaction.</span></p>
<ul><li>when coadministered with ritonavir in patients receiving the antiarrhythmic agents flecainide and propafenone. If LEXIVA is coadministered with ritonavir, reference should be made to the full prescribing information for ritonavir for additional contraindications. </li></ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_f3d8d33d-a41e-4e93-90eb-1d998316fc50"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_129ef7ab-c0a8-4ce4-9dd6-3c203cf64ed4"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1</span> Drug Interactions</h2>
<p class="First"> See Table 1 for listings of drugs that are contraindicated due to potentially life-threatening adverse events, significant drug interactions, or due to loss of virologic activity <span class="Italics">[see Contraindications (4), Drug Interactions (7.2)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ce7de3c6-76cd-4440-ab19-e5749c421a27"></a><a name="section-5.2"></a><p></p>
<h2>
<span class="Bold">5.2</span> <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First"> Severe and life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including 1Â case of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> among 700Â patients treated with LEXIVA in clinical studies. Treatment with LEXIVA should be discontinued for severe or life-threatening <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> and for moderate <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> accompanied by systemic symptoms <span class="Italics">[see Adverse Reactions (6)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a23fda85-fa84-4508-9b48-4d9cbe84d8ea"></a><a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.3</span> Sulfa <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></h2>
<p class="First"> LEXIVA should be used with caution in patients with a known <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">sulfonamide allergy</span>. Fosamprenavir contains a sulfonamide moiety. The potential for cross-sensitivity between drugs in the sulfonamide class and fosamprenavir is unknown. In a clinical study of LEXIVA used as the sole protease inhibitor, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurred in 2 of 10Â patients (20%) with a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">sulfonamide allergy</span> compared with 42 of 126 patients (33%) with no history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">sulfonamide allergy</span>. In 2Â clinical studies of LEXIVA plus low-dose ritonavir, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurred in 8 of 50Â patients (16%) with a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">sulfonamide allergy</span> compared with 50 of 412Â patients (12%) with no history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">sulfonamide allergy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff9c3011-9e2d-48a0-ab4c-d1b38804270c"></a><a name="section-5.4"></a><p></p>
<h2>
<span class="Bold">5.4</span> Hepatic Toxicity</h2>
<p class="First">Use of LEXIVA with ritonavir at higher-than-recommended dosages may result in transaminase elevations and should not be used <span class="Italics">[see Dosage and Administration (2), Overdosage (10)]</span>. Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C or marked elevations in transaminases prior to treatment may be at increased risk for developing or worsening of transaminase elevations. Appropriate laboratory testing should be conducted prior to initiating therapy with LEXIVA and patients should be monitored closely during treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67cb4cc1-60d9-4fe3-a150-2eedf4617c99"></a><a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.5</span> <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>/<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></h2>
<p class="First"> New onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, exacerbation of pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been reported during postmarketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> has occurred. In those patients who discontinued protease inhibitor therapy, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and causal relationships between protease inhibitor therapy and these events have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12b46f14-971a-495f-93be-4b61e25bbcac"></a><a name="section-5.6"></a><p></p>
<h2>
<span class="Bold">5.6</span> <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including LEXIVA. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d99499a7-8049-45c8-9e6e-4c50087a7177"></a><a name="section-5.7"></a><p></p>
<h2>
<span class="Bold">5.7</span> Fat Redistribution</h2>
<p class="First"> Redistribution/accumulation of body fat, including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearance,â€? have been observed in patients receiving antiretroviral therapy, including LEXIVA. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ae259e3-a8bc-44ab-83ec-cd503454891c"></a><a name="section-5.8"></a><p></p>
<h2>
<span class="Bold">5.8</span> Lipid Elevations</h2>
<p class="First"> Treatment with LEXIVA plus ritonavir has resulted in increases in the concentration of triglycerides and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span><span class="Italics"> [see Adverse Reactions (6)]</span>. Triglyceride and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> testing should be performed prior to initiating therapy with LEXIVA and at periodic intervals during therapy. Lipid disorders should be managed as clinically appropriate <span class="Italics">[see Drug Interactions (7)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ce4e0e4-cc18-4d14-956b-b4089a69af76"></a><a name="section-5.9"></a><p></p>
<h2>
<span class="Bold">5.9</span> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic Anemia</span></h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Acute hemolytic anemia</span> has been reported in a patient treated with amprenavir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94ff40ee-aa21-4619-8c00-5634aa572f2d"></a><a name="section-5.10"></a><p></p>
<h2>
<span class="Bold">5.10</span> Patients With <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span></h2>
<p class="First">There have been reports of spontaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> and B treated with protease inhibitors. In some patients, additional factor VIII was required. In many of the reported cases, treatment with protease inhibitors was continued or restarted. A causal relationship between protease inhibitor therapy and these episodes has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3ce661e-b65b-4b92-b395-a1b53816532d"></a><a name="section-5.11"></a><p></p>
<h2>
<span class="Bold">5.11</span> <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span></h2>
<p class="First"> Cases of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> were reported during postmarketing surveillance in HIV-infected patients receiving LEXIVA.Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> occur, temporary interruption or discontinuation of therapy may be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_71f5222c-fc36-4ee6-8953-c811be7dbb75"></a><a name="section-5.12"></a><p></p>
<h2>
<span class="Bold">5.12</span> Resistance/Cross-Resistance</h2>
<p class="First"> Because the potential for HIV cross-resistance among protease inhibitors has not been fully explored, it is unknown what effect therapy with LEXIVA will have on the activity of subsequently administered protease inhibitors. LEXIVA has been studied in patients who have experienced treatment failure with protease inhibitors <span class="Italics">[see Clinical Studies (14.2)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_714e0f16-5484-48a6-be7d-d77d7e635a4c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<ul>
<li>Severe or life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been reported with the use of LEXIVA <span class="Italics">[see Warnings and Precautions (5.2)].</span>
</li>
<li>The most common moderate to severe adverse reactions in clinical studies of LEXIVA were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</li>
<li>Treatment discontinuation due to adverse events occurred in 6.4% of patients receiving LEXIVA and in 5.9% of patients receiving comparator treatments. The most common adverse reactions leading to discontinuation of LEXIVA (incidence â‰¤1% of patients) included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, AST increased, ALT increased, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c148f4c-9704-4ee9-8ae7-2ec7b16fca3a"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials </h2>
<p class="First"><span class="Underline">Adults</span></p>
<p>Â  The data for the 3Â active-controlled clinical trials described below reflect exposure of 700Â HIV-1 infected patients to LEXIVA Tablets, including 599Â patients exposed to LEXIVA for &gt;24Â weeks, and 409Â patients exposed for &gt;48Â weeks. The population age ranged from 17 to 72Â years. Of these patients, 26% were female, 51% Caucasian, 31% black, 16% American Hispanic, and 70% were antiretroviral-naive. Sixty-one percent received LEXIVA 1,400Â mg once daily plus ritonavir 200Â mg once daily, 24% received LEXIVA 1,400Â mg twice daily, and 15% received LEXIVA 700Â mg twice daily plus ritonavir 100Â mg twice daily.</p>
<p> Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p> Selected adverse reactions reported during the clinical efficacy studies of LEXIVA are shown in TablesÂ 2 and 3. Each table presents adverse reactions of moderate or severe intensity in patients treated with combination therapy for up to 48Â weeks.</p>
<p>Table 2. Selected Moderate/Severe Clinical Adverse Reactions Reported in â‰¥2% of Antiretroviral-Naive Adult Patients </p>
<a name="id_0456736e-a087-447d-8293-32a1ee665725"></a><table border="single" width="469.000">
<col width="28.8%">
<col width="18.3%">
<col width="17.3%">
<col width="19.2%">
<col width="16.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Adverse Reaction</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">APV30001<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">APV30002<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">LEXIVA</p>
<p>1,400Â mg b.i.d.</p>
(nÂ =Â 166)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Nelfinavir</p>
<p>1,250Â mg b.i.d.</p>
(nÂ =Â 83)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">LEXIVA</p>
<p>1,400Â mg q.d./</p>
<p>Ritonavir </p>
<p>200Â mg q.d.</p>
(nÂ =Â 322)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Nelfinavir</p>
<p>1,250Â mg b.i.d.</p>
(nÂ =Â 327)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Gastrointestinal</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Rrule" align="center" valign="top">5%</td>
<td class="Rrule" align="center" valign="top">18%</td>
<td class="Rrule" align="center" valign="top">10%</td>
<td class="Rrule" align="center" valign="top">18%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center" valign="top">7%</td>
<td class="Rrule" align="center" valign="top">4%</td>
<td class="Rrule" align="center" valign="top">7%</td>
<td class="Rrule" align="center" valign="top">5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center" valign="top">2%</td>
<td class="Rrule" align="center" valign="top">4%</td>
<td class="Rrule" align="center" valign="top">6%</td>
<td class="Rrule" align="center" valign="top">4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center" valign="top">1%</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Rrule" align="center" valign="top">2%</td>
<td class="Rrule" align="center" valign="top">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center" valign="top">8%</td>
<td class="Rrule" align="center" valign="top">2%</td>
<td class="Rrule" align="center" valign="top">3%</td>
<td class="Rrule" align="center" valign="top">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">General disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center" valign="top">2%</td>
<td class="Rrule" align="center" valign="top">1%</td>
<td class="Rrule" align="center" valign="top">4%</td>
<td class="Rrule" align="center" valign="top">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Nervous system</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center" valign="top">2%</td>
<td class="Rrule" align="center" valign="top">4%</td>
<td class="Rrule" align="center" valign="top">3%</td>
<td class="Botrule Rrule" align="center" valign="top">3%</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>All patients also received abacavir and lamivudine twice daily.</p>
<p>Table 3. Selected Moderate/Severe Clinical Adverse Reactions Reported in â‰¥2% of Protease Inhibitor-Experienced Adult Patients (Study APV30003)</p>
<a name="id_c6af543d-c971-4146-9a6f-4b3f776938e2"></a><table border="single" width="462.000">
<col width="34.4%">
<col width="33.1%">
<col width="32.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Adverse Reaction</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">LEXIVA 700Â mg b.i.d./</p>
<p>Ritonavir 100Â mg b.i.d.<span class="Sup">a</span></p>
(nÂ =Â 106)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Lopinavir 400Â mg b.i.d./</p>
<p>Ritonavir 100Â mg b.i.d.<span class="Sup">a</span></p>
(nÂ =Â 103)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Gastrointestinal</span></td>
<td class="Rrule" align="right" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Rrule" align="center" valign="top">13%</td>
<td class="Rrule" align="center" valign="top">11%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center" valign="top">3%</td>
<td class="Rrule" align="center" valign="top">9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center" valign="top">3%</td>
<td class="Rrule" align="center" valign="top">5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center" valign="top">&lt;1%</td>
<td class="Rrule" align="center" valign="top">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center" valign="top">3%</td>
<td class="Rrule" align="center" valign="top">0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Nervous system</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center" valign="top">4%</td>
<td class="Botrule Rrule" align="center" valign="top">2%</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>All patients also received 2 reverse transcriptase inhibitors.</p>
<p> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> (without regard to causality) occurred in approximately 19% of patients treated with LEXIVA in the pivotal efficacy studies. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> were usually maculopapular and of mild or moderate intensity, some with <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> had a median onset of 11Â days after initiation of LEXIVA and had a median duration of 13Â days. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> led to discontinuation of LEXIVA in &lt;1% of patients. In some patients with mild or moderate <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, dosing with LEXIVA was often continued without interruption; if interrupted, reintroduction of LEXIVA generally did not result in <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> recurrence. </p>
<p> The percentages of patients with Grade 3 or 4 laboratory abnormalities in the clinical efficacy studies of LEXIVA are presented in TablesÂ 4 and 5.</p>
<p>Table 4. Grade 3/4 Laboratory Abnormalities Reported in â‰¥2% of Antiretroviral-Naive Adult Patients in Studies APV30001 and APV30002 </p>
<a name="id_4fee0de9-65db-4f49-aa2e-7d9a0f65d800"></a><table border="single" width="469.000">
<col width="39.9%">
<col width="13.4%">
<col width="15.4%">
<col width="17.3%">
<col width="14.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Laboratory Abnormality</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">APV30001<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">APV30002<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First">LEXIVA</p>
<p>1,400Â mg b.i.d.</p>
(nÂ =Â 166)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Nelfinavir</p>
<p>1,250Â mg b.i.d.</p>
(nÂ =Â 83)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">LEXIVA</p>
<p>1,400Â mg q.d./</p>
<p>Ritonavir </p>
<p>200Â mg q.d.</p>
(nÂ =Â 322)</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Nelfinavir</p>
<p>1,250Â mg b.i.d.</p>
(nÂ =Â 327)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">ALT (&gt;5 x ULN)</td>
<td class="Rrule" align="center" valign="top">6%</td>
<td class="Rrule" align="center" valign="top">5%</td>
<td class="Rrule" align="center" valign="top">8%</td>
<td class="Rrule" align="center" valign="top">8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">AST (&gt;5 x ULN)</td>
<td class="Rrule" align="center" valign="top">6%</td>
<td class="Rrule" align="center" valign="top">6%</td>
<td class="Rrule" align="center" valign="top">6%</td>
<td class="Rrule" align="center" valign="top">7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Serum lipase (&gt;2 x ULN)</td>
<td class="Rrule" align="center" valign="top">8%</td>
<td class="Rrule" align="center" valign="top">4%</td>
<td class="Rrule" align="center" valign="top">6%</td>
<td class="Rrule" align="center" valign="top">4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Triglycerides<span class="Sup">b</span> (&gt;750Â mg/dL)</td>
<td class="Rrule" align="center" valign="top">0%</td>
<td class="Rrule" align="center" valign="top">1%</td>
<td class="Rrule" align="center" valign="top">6%</td>
<td class="Rrule" align="center" valign="top">2%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Neutrophil count, absolute (&lt;750Â cells/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center" valign="top">3%</td>
<td class="Rrule" align="center" valign="top">6%</td>
<td class="Rrule" align="center" valign="top">3%</td>
<td class="Botrule Rrule" align="center" valign="top">4%</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>All patients also received abacavir and lamivudine twice daily. </p>
<p><span class="Sup">b</span>Fasting specimens.</p>
<p>ULN =Â Upper limit of normal.</p>
<p> The incidence of Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> in antiretroviral-naive patients who received LEXIVA in the pivotal studies was &lt;1%.</p>
<p>Table 5. Grade 3/4 Laboratory Abnormalities Reported in â‰¥2% of Protease Inhibitor-Experienced Adult Patients in Study APV30003 </p>
<a name="id_d6dfd9a3-0cea-4c82-8bc1-46f9510f78de"></a><table border="single" width="461.000">
<col width="37.5%">
<col width="29.3%">
<col width="33.2%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Laboratory Abnormality</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">LEXIVA 700Â mg b.i.d./</p>
<p>Ritonavir 100Â mg b.i.d.<span class="Sup">a</span></p>
(nÂ =Â 104)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Lopinavir 400Â mg b.i.d./</p>
<p>Ritonavir 100Â mg b.i.d.<span class="Sup">a</span></p>
(nÂ =Â 103)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Triglycerides<span class="Sup">b</span> (&gt;750Â mg/dL)</td>
<td class="Rrule" align="center" valign="top">11%<span class="Sup">c</span>
</td>
<td class="Rrule" align="center" valign="top">6%<span class="Sup">c</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Serum lipase (&gt;2 x ULN)</td>
<td class="Rrule" align="center" valign="top">5%</td>
<td class="Rrule" align="center" valign="top">12%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">ALT (&gt;5 x ULN)</td>
<td class="Rrule" align="center" valign="top">4%</td>
<td class="Rrule" align="center" valign="top">4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">AST (&gt;5 x ULN)</td>
<td class="Rrule" align="center" valign="top">4%</td>
<td class="Rrule" align="center" valign="top">2%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Glucose (&gt;251Â mg/dL)</td>
<td class="Rrule" align="center" valign="top">2%<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2%<span class="Sup">c</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>All patients also received 2Â reverse transcriptase inhibitors.</p>
<p><span class="Sup">b</span>Fasting specimens.</p>
<p><span class="Sup">c</span>nÂ =Â 100 for LEXIVA plus ritonavir, nÂ =Â 98 for lopinavir plus ritonavir.</p>
<p>ULN =Â Upper limit of normal.</p>
<p><span class="Underline">Pediatric Patients:</span> LEXIVA with and without ritonavir was studied in 144Â pediatric patients 2 to 18Â years of age in 2Â open-label studies. Safety information from 75Â pediatric patients receiving LEXIVA twice daily with or without ritonavir follows. </p>
<p> All adverse events regardless of causality, all drug-related adverse events, and all laboratory events occurred with similar frequency in pediatrics compared with adults, with the exception of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, regardless of causality, occurred more frequently among pediatric patients receiving LEXIVA twice daily with ritonavir ([30%] all between 2 and 18Â years of age) and without ritonavir ([56%] all between 2 and 5Â years of age) compared with adults receiving LEXIVA twice daily with ritonavir (10%) and without ritonavir (16%). The median duration of drug-related <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> episodes was 1Â day (range: 1 to 62Â days). <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> required temporary dose interruptions in 4Â pediatric patients and was treatment-limiting in 1Â pediatric patient, all of whom were receiving LEXIVA twice daily with ritonavir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31d1339c-482a-4b3e-b32c-70f39dce9960"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following reactions have been identified during post-approval use of LEXIVA. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to LEXIVA.Â  </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>.</p>
<p><span class="Underline">Metabolism and Nutrition Disorders </span></p>
<p><span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p>
<p>Oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
<p><span class="Underline">Skin and Subcutaneous Tissue Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>. </p>
<p><span class="Underline">Urogenital</span></p>
<p><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_7a567ca0-a6e5-45d6-af71-6fe6be5cb6fb"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">See also Contraindications (4), Clinical Pharmacology (12.3)</span>.</p>
<p> If LEXIVA is used in combination with ritonavir, see full prescribing information for ritonavir for additional information on drug interactions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fda664ff-d79c-404a-a695-6580f0597886"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP Inhibitors and Inducers</h2>
<p class="First"> Amprenavir, the active metabolite of fosamprenavir, is an inhibitor of cytochrome P450 3A4 metabolism and therefore should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4. Data also suggest that amprenavir induces CYP3A4.</p>
<p> Amprenavir is metabolized by CYP3A4. Coadministration of LEXIVA and drugs that induce CYP3A4, such as rifampin, may decrease amprenavir concentrations and reduce its therapeutic effect. Coadministration of LEXIVA and drugs that inhibit CYP3A4 may increase amprenavir concentrations and increase the incidence of adverse effects.</p>
<p> The potential for drug interactions with LEXIVA changes when LEXIVA is coadministered with the potent CYP3A4 inhibitor ritonavir. The magnitude of CYP3A4-mediated drug interactions (effect on amprenavir or effect on coadministered drug) may change when LEXIVA is coadministered with ritonavir. Because ritonavir is a CYP2D6 inhibitor, clinically significant interactions with drugs metabolized by CYP2D6 are possible when coadministered with LEXIVA plus ritonavir.</p>
<p> There are other agents that may result in serious and/or life-threatening drug interactions <span class="Italics">[see Contraindications (4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9aad74c2-e44d-4b0e-ad61-da674e7699d1"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs That Should Not Be Coadministered With LEXIVA</h2>
<p class="First"><span class="Italics">See Contraindications (4).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_36b3f437-e606-4a8e-9285-9ee6021d643b"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Established and Other Potentially Significant Drug Interactions</h2>
<p class="First"> Table 6 provides a listing of established or potentially clinically significant drug interactions. Information in the table applies to LEXIVA with or without ritonavir, unless otherwise indicated.</p>
<p>Table 6. Established and Other Potentially Significant Drug Interactions</p>
<a name="id_ae2279a9-65b7-4fd8-bb16-c89bd6699605"></a><table border="single" width="441.000">
<col width="30.6%">
<col width="26.5%">
<col width="42.9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Concomitant Drug Class: Drug Name</td>
<td class="Botrule Rrule" align="center" valign="top">Effect on Concentration of Amprenavir or Concomitant Drug</td>
<td class="Botrule Rrule" align="center" valign="top">Clinical Comment</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><span class="Bold"><span class="Italics">HIV-Antiviral Agents</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span> Efavirenz<span class="Sup">a</span></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†“Amprenavir</p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
â†“Amprenavir</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Appropriate doses of the combinations with respect to safety and efficacy have not been established. </p>
An additional 100Â mg/day (300Â mg total) of ritonavir is recommended when efavirenz is administered with LEXIVA/ritonavir once daily. No change in the ritonavir dose is required when efavirenz is administered with LEXIVA plus ritonavir twice daily. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span></p>
Nevirapine<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†“Amprenavir </p>
<p>â†‘Nevirapine</p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
<p>â†“Amprenavir</p>
<p>â†‘Nevirapine</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Coadministration of nevirapine and LEXIVA without ritonavir is not recommended.</p>
<p>No dosage adjustment required when nevirapine is administered with LEXIVA/ritonavir twice daily. </p>
The combination of nevirapine administered with LEXIVA/ritonavir once-daily regimen has not been studied.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">HIV protease inhibitor:</span></p>
Atazanavir<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>Interaction has not been evaluated.</p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
<p>â†“Atazanavir</p>
â†”Amprenavir</td>
<td class="Botrule Rrule" align="left" valign="top">Appropriate doses of the combinations with respect to safety and efficacy have not been established.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">HIV protease inhibitors:</span></p>
Indinavir<span class="Sup">a</span>, nelfinavir<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†‘Amprenavir</p>
<p>Effect on indinavir and nelfinavir is not well established.</p>
<span class="Bold">LEXIVA/ritonavir:</span> Interaction has not been evaluated.</td>
<td class="Botrule Rrule" align="left" valign="top">Appropriate doses of the combinations with respect to safety and efficacy have not been established. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">HIV protease inhibitors:</span></p>
Lopinavir/ritonavir<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">â†“Amprenavir</p>
<p>â†“Lopinavir</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">An increased rate of adverse events has been observed. Appropriate doses of the combinations with respect to safety and efficacy have not been established.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">HIV protease inhibitor:</span></p>
Saquinavir<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†“Amprenavir</p>
<p>Effect on saquinavir is not well established.</p>
<span class="Bold">LEXIVA/ritonavir:</span> Interaction has not been evaluated.</td>
<td class="Botrule Rrule" align="left" valign="top">Appropriate doses of the combination with respect to safety and efficacy have not been established.</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><span class="Bold"><span class="Italics">Other Agents</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Antiarrhythmics:</span></p>
Amiodarone, bepridil, lidocaine (systemic), and quinidine</td>
<td class="Botrule Rrule" align="left" valign="top"><p class="First">â†‘Antiarrhythmics</p></td>
<td class="Botrule Rrule" align="left" valign="top">Use with caution. Increased exposure may be associated with life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. Therapeutic concentration monitoring, if available, is recommended for antiarrhythmics. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Anticoagulant:</span></p>
Warfarin</td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Concentrations of warfarin may be affected. It is recommended that INR (international normalized ratio) be monitored. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Anticonvulsants:</span></p>
<p>Carbamazepine, phenobarbital, phenytoin</p>
<p>Phenytoin<span class="Sup">a</span></p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†“Amprenavir</p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
<p>â†‘Amprenavir</p>
<p>â†“Phenytoin</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Use with caution. LEXIVA may be less effective due to decreased amprenavir plasma concentrations in patients taking these agents concomitantly. </p>
Plasma phenytoin concentrations should be monitored and phenytoin dose should be increased as appropriate. No change in LEXIVA/ritonavir dose is recommended.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Antidepressant:</span></p>
Paroxetine, trazodone</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">â†“Paroxetine</p>
â†‘Trazodone</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Coadministration of paroxetine with LEXIVA/ritonavir significantly decreased plasma levels of paroxetine. Any paroxetine dose adjustment should be guided by clinical effect (tolerability and efficacy).</p>
Concomitant use of trazodone and LEXIVA with or without ritonavir may increase plasma concentrations of trazodone. Adverse events of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as LEXIVA, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Antifungals:</span></p>
Ketoconazole<span class="Sup">a</span>, itraconazole</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">â†‘Ketoconazole</p>
â†‘Itraconazole</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Increase monitoring for adverse events. </p>
<p><span class="Bold">LEXIVA:</span></p>
<p>Dose reduction of ketoconazole or itraconazole may be needed for patients receiving more than 400Â mg ketoconazole or itraconazole per day. </p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
High doses of ketoconazole or itraconazole (&gt;200Â mg/day) are not recommended.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Antimycobacterial:</span></p>
Rifabutin<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘Rifabutin and rifabutin metabolite</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">A complete blood count should be performed weekly and as clinically indicated to monitor for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. </p>
<p><span class="Bold">LEXIVA:</span></p>
<p>A dosage reduction of rifabutin by at least half the recommended dose is required. </p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
Dosage reduction of rifabutin by at least 75% of the usual dose of 300Â mg/day is recommended (a maximum dose of 150Â mg every other day or 3Â times per week).</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Benzodiazepines: </span></p>
Alprazolam, clorazepate, diazepam, flurazepam</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘Benzodiazepines</td>
<td class="Botrule Rrule" align="left" valign="top">Clinical significance is unknown. A decrease in benzodiazepine dose may be needed. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Calcium channel blockers:</span></p>
Diltiazem, felodipine, nifedipine, nicardipine, nimodipine, verapamil, amlodipine, nisoldipine, isradipine</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘Calcium channel blockers</td>
<td class="Botrule Rrule" align="left" valign="top">Use with caution. Clinical monitoring of patients is recommended. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Corticosteroid:</span> Dexamethasone</td>
<td class="Botrule Rrule" align="left" valign="top">â†“Amprenavir</td>
<td class="Botrule Rrule" align="left" valign="top">Use with caution. LEXIVA may be less effective due to decreased amprenavir plasma concentrations. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Histamine H<span class="Sub">2</span>-receptor antagonists:</span></p>
<p>Cimetidine, famotidine, nizatidine, ranitidine<span class="Sup">a</span></p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†“Amprenavir</p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
Interaction not evaluated</td>
<td class="Botrule Rrule" align="left" valign="top">Use with caution. LEXIVA may be less effective due to decreased amprenavir plasma concentrations.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">HMG-CoA reductase inhibitor:</span></p>
Atorvastatin<span class="Sup">a</span>, rosuvastatin</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">â†‘Atorvastatin</p>
â†‘Rosuvastatin</td>
<td class="Botrule Rrule" align="left" valign="top">Use the lowest possible dose of atorvastatin or rosuvastatin with careful monitoring, or consider other HMG-CoA reductase inhibitors such as fluvastatin or pravastatin. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Immunosuppressants:</span></p>
Cyclosporine, tacrolimus, rapamycin</td>
<td class="Botrule Rrule" align="left" valign="top">â†‘Immunosuppressants</td>
<td class="Botrule Rrule" align="left" valign="top">Therapeutic concentration monitoring is recommended for immunosuppressant agents. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Inhaled/nasal steroid:</span></p>
Fluticasone</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†‘Fluticasone</p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
<p>â†‘Fluticasone</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Use with caution. Consider alternatives to fluticasone, particularly for long-term use.</p>
May result in significantly reduced serum cortisol concentrations. Systemic corticosteroid effects including <span class="product-label-link" type="condition" conceptid="195212" conceptname="Hypercortisolism">Cushings syndrome</span> and adrenal suppression have been reported during postmarketing use in patients receiving ritonavir and inhaled or intranasally administered fluticasone. Coadministration of fluticasone and LEXIVA/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Narcotic analgesic:</span></p>
Methadone</td>
<td class="Botrule Rrule" align="left" valign="top">â†“Methadone</td>
<td class="Botrule Rrule" align="left" valign="top">Data suggest that the interaction is not clinically relevant; however, patients should be monitored for opiate withdrawal symptoms.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Oral contraceptives:</span></p>
EthinylÂ estradiol/norethin-drone<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†“Amprenavir</p>
<p>â†“Ethinyl estradiol</p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
<p>â†“Ethinyl estradiol</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Alternative methods of non-hormonal contraception are recommended.</p>
<p>May lead to loss of virologic response. <span class="Sup">*</span></p>
Increased risk of transaminase elevations. No data are available on the use of LEXIVA/ritonavir with other hormonal therapies, such as hormone replacement therapy (HRT) for postmenopausal women.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">PDE5 inhibitors:</span></p>
<p>Sildenafil, tadalafil, vardenafil</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">â†‘Sildenafil</p>
<p>â†‘Tadalafil</p>
<p>â†‘Vardenafil</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">May result in an increase in PDE5 inhibitor-associated adverse events, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, visual changes, and <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>.</p>
<p><span class="Bold">LEXIVA:</span></p>
<p>Sildenafil: 25Â mg every 48Â hours. </p>
<p>Tadalafil: no more than 10Â mg every 72Â hours. </p>
<p>Vardenafil: no more than 2.5Â mg every 24Â hours. </p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
<p>Sildenafil: 25Â mg every 48Â hours.</p>
<p>Tadalafil: no more than 10Â mg every 72Â hours.</p>
Vardenafil: no more than 2.5Â mg every 72Â hours.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Proton pump inhibitors:</span></p>
<p>Esomeprazole<span class="Sup">a</span>, lansoprazole, omeprazole, pantoprazole, rabeprazole</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">LEXIVA:</span></p>
<p>â†”Amprenavir</p>
<p>â†‘Esomeprazole</p>
<p><span class="Bold">LEXIVA/ritonavir:</span></p>
<p>â†”Amprenavir</p>
â†”Esomeprazole</td>
<td class="Botrule Rrule" align="left" valign="top">Proton pump inhibitors can be administered at the same time as a dose of LEXIVA with no change in plasma amprenavir concentrations.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Tricyclic antidepressants:</span></p>
Amitriptyline, imipramine</td>
<td class="Rrule" align="left" valign="top">â†‘Tricyclics</td>
<td class="Botrule Rrule" align="left" valign="top">Therapeutic concentration monitoring is recommended for tricyclic antidepressants. </td>
</tr>
</tbody>
</table>
<p><span class="Sup">a Â </span><span class="Italics">See Clinical Pharmacology (12.3) Tables 10, 11, 12, or 13 for magnitude of interaction.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_6ef33f83-f269-45fd-bf1b-e2f92dff4406"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_60fa140b-3e14-42b1-9e68-a6a97623d084"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"> Pregnancy Category C. Embryo/fetal development studies were conducted in rats (dosed from day 6 to day 17 of gestation) and rabbits (dosed from day 7 to day 20 of gestation). Administration of fosamprenavir to pregnant rats and rabbits produced no major effects on embryo-fetal development; however, the incidence of abortion was increased in rabbits that were administered fosamprenavir. Systemic exposures (AUC<span class="Sub">0-24 hr</span>) to amprenavir at these dosages were 0.8 (rabbits) to 2 (rats) times the exposures in humans following administration of the maximum recommended human dose (MRHD) of fosamprenavir alone or 0.3 (rabbits) to 0.7 (rats) times the exposures in humans following administration of the MRHD of fosamprenavir in combination with ritonavir. In contrast, administration of amprenavir was associated with abortions and an increased incidence of minor skeletal variations resulting from deficient ossification of the femur, humerus, and trochlea, in pregnant rabbits at the tested dose; approximately one-twentieth the exposure seen at the recommended human dose.</p>
<p> The mating and fertility of the F<span class="Sub">1</span> generation born to female rats given fosamprenavir was not different from control animals; however, fosamprenavir did cause a reduction in both pup survival and body weights. Surviving F<span class="Sub">1</span> female rats showed an increased time to successful mating, an increased length of gestation, a reduced number of uterine implantation sites per litter, and reduced gestational body weights compared with control animals. Systemic exposure (AUC<span class="Sub">0-24Â hr</span>) to amprenavir in the F<span class="Sub">0</span> pregnant rats was approximately 2Â times higher than exposures in humans following administration of the MRHD of fosamprenavir alone or approximately the same as those seen in humans following administration of the MRHD of fosamprenavir in combination with ritonavir.</p>
<p> There are no adequate and well-controlled studies in pregnant women. LEXIVA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p><span class="Underline">Antiretroviral Pregnancy Registry</span></p>
<p>To monitor maternal-fetal outcomes of pregnant women exposed to LEXIVA, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4f0c6907-1459-4a29-b935-9f56a29415b1"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Â  The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV. Although it is not known if amprenavir is excreted in human milk, amprenavir is secreted into the milk of lactating rats. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving LEXIVA. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f5492a39-7e2a-43a8-9fb8-0341615641c1"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"> The safety, pharmacokinetic profile, and virologic response of LEXIVA Oral Suspension and Tablets were evaluated in pediatric patients 2 to 18Â years of age in 2Â open-label studies <span class="Italics">[see Clinical Studies (14.3)]</span>. No data are available for pediatric patients &lt;2Â years of age. </p>
<p> The adverse reaction profile seen in pediatrics was similar to that seen in adults. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, regardless of causality, was more frequent in pediatrics than in adults <span class="Italics">[see Adverse Reactions (6.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_c55f4691-e991-4de9-b5f0-1ff209407112"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Â  Clinical studies of LEXIVA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger adults. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58f33ce9-f58f-461c-9088-d601d935a31a"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Â  Amprenavir is principally metabolized by the liver; therefore, caution should be exercised when administering LEXIVA to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> because amprenavir concentrations may be increased <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. Patients with impaired hepatic function receiving LEXIVA with or without concurrent ritonavir require dose reduction <span class="Italics">[see Dosage and Administration (2.3)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_352d1b3d-d48d-481d-85d1-539f8b9cc346"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"> In a healthy volunteer repeat-dose pharmacokinetic study evaluating high-dose combinations of LEXIVA plus ritonavir, an increased frequency of Grade 2/3 ALT elevations (&gt;2.5 x ULN) was observed with LEXIVA 1,400Â mg twice daily plus ritonavir 200Â mg twice daily (4 of 25Â subjects). Concurrent Grade 1/2 elevations in AST (&gt;1.25 x ULN) were noted in 3 of these 4Â subjects. These transaminase elevations resolved following discontinuation of dosing. </p>
<p> There is no known antidote for LEXIVA. It is not known whether amprenavir can be removed by peritoneal dialysis or hemodialysis. If overdosage occurs, the patient should be monitored for evidence of toxicity and standard supportive treatment applied as necessary. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d9e30dcf-1521-4660-844f-8973f14e89c5"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"> LEXIVA (fosamprenavir calcium) is a prodrug of amprenavir, an inhibitor of HIV protease. The chemical name of fosamprenavir calcium is (3<span class="Italics">S</span>)-tetrahydrofuran-3-yl (1<span class="Italics">S</span>,2<span class="Italics">R</span>)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy) propylcarbamate monocalcium salt. Fosamprenavir calcium is a single stereoisomer with the (3<span class="Italics">S</span>)(1<span class="Italics">S</span>,2<span class="Italics">R</span>) configuration. It has a molecular formula of C<span class="Sub">25</span>H<span class="Sub">34</span>CaN<span class="Sub">3</span>O<span class="Sub">9</span>PS and a molecular weight of 623.7. It has the following structural formula:</p>
<div class="Figure"><img alt="fosamprenavir calcium chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=009575f9-74e8-4a6d-9fa6-3cae72fd01c3&amp;name=26d3b057-5dd8-4bd5-8c05-2f9c28be35c4-01.jpg"></div>
<p> Fosamprenavir calcium is a white to cream-colored solid with a solubility of approximately 0.31Â mg/mL in water at 25Â°C. </p>
<p> LEXIVA Tablets are available for oral administration in a strength of 700Â mg of fosamprenavir as fosamprenavir calcium (equivalent to approximately 600Â mg of amprenavir). Each 700-mg tablet contains the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and povidone K30. The tablet film-coating contains the inactive ingredients hypromellose, iron oxide red, titanium dioxide, and triacetin. </p>
<p> LEXIVA Oral Suspension is available in a strength of 50Â mg/mL of fosamprenavir as fosamprenavir calcium equivalent to approximately 43Â mg of amprenavir. LEXIVA Oral Suspension is a white to off-white suspension with a grape-bubblegum-peppermint flavor. Each one milliliter (1Â mL) contains the inactive ingredients artificial grape-bubblegum flavor, calcium chloride dihydrate, hypromellose, methylparaben, natural peppermint flavor, polysorbate 80, propylene glycol, propylparaben, purified water, and sucralose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e9baa4e4-af05-436c-be97-e68ef4b1047f"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_edca0357-fa21-4866-b59e-6f5fbdb01a0b"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"> Fosamprenavir is an antiviral agent <span class="Italics">[see Clinical Pharmacology (12.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_effc33fb-345e-4788-bdbe-a178c0ddc5d3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"> The pharmacokinetic properties of amprenavir after administration of LEXIVA, with or without ritonavir, have been evaluated in both healthy adult volunteers and in HIV-infected patients; no substantial differences in steady-state amprenavir concentrations were observed between the 2Â populations. </p>
<p> The pharmacokinetic parameters of amprenavir after administration of LEXIVA (with and without concomitant ritonavir) are shown in Table 7.</p>
<a name="id_dd8b5447-0345-4243-a053-02d135d228e3"></a><table width="467.000">
<caption><span>Table 7. Geometric Mean (95% CI) Steady-State Plasma Amprenavir Pharmacokinetic Parameters in Adults</span></caption>
<col width="18.4%">
<col width="19.3%">
<col width="18.8%">
<col width="18.8%">
<col width="24.6%">
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" rowspan="1" valign="top"><p class="First"><span class="Sup">a</span>Data shown are median (range).</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" rowspan="1" valign="top"><p class="First">Regimen</p></td>
<td class="Toprule" align="center" rowspan="1" valign="top">
<p class="First">C<span class="Sub">max</span></p>
<p>(mcg/mL)</p>
</td>
<td class="Toprule" align="center" rowspan="1" valign="top">
<p class="First">T<span class="Sub">max </span></p>
<p>(hours)<span class="Bold"><span class="Sup">a</span></span></p>
</td>
<td class="Toprule" align="center" rowspan="1" valign="top">
<p class="First">AUC<span class="Sub">24 </span></p>
<p>(mcgâ€¢hr/mL)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">C<span class="Sub">min</span></p>
<p>Â  (mcg/mL)</p>
</td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">LEXIVA 1,400Â mg b.i.d.</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">4.82</p>
<p>(4.06-5.72)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">1.3</p>
<p>(0.8-4.0)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">33.0</p>
<p>(27.6-39.2)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">0.35</p>
<p>(0.27-0.46)</p>
</td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">LEXIVA 1,400Â mg q.d. plus Ritonavir 200Â mg q.d.</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">7.24</p>
<p>(6.32-8.28)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">2.1</p>
<p>(0.8-5.0)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">69.4 </p>
<p>(59.7-80.8)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">1.45</p>
<p>(1.16-1.81)</p>
</td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">LEXIVA 1,400Â mg q.d. plus Ritonavir 100Â mg q.d. </p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">7.93</p>
<p>(7.25-8.68)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">1.5</p>
<p>(0.75-5.0)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">66.4</p>
<p>(61.1-72.1)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">0.86</p>
<p>(0.74-1.01)</p>
</td>
</tr>
<tr class="Last">
<td align="left" rowspan="1" valign="top"><p class="First">LEXIVA 700Â mg b.i.d. plus Ritonavir 100Â mg b.i.d.</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">6.08</p>
<p>(5.38-6.86)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">1.5</p>
<p>(0.75-5.0)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">79.2</p>
<p>(69.0-90.6)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">2.12</p>
<p>(1.77-2.54)</p>
</td>
</tr>
</tbody>
</table>
<p> The mean plasma amprenavir concentrations of the dosing regimens over the dosing intervals are displayed in Figure 1. </p>
<div class="Figure">
<img alt="Figure 1. Mean (ï‚±SD) Steady State Plasma Amprenavir Concentrations and Mean IC50 Values Against HIV from Protease Inhibitor Naive Patients (in the Absence of Human Serum)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=009575f9-74e8-4a6d-9fa6-3cae72fd01c3&amp;name=26d3b057-5dd8-4bd5-8c05-2f9c28be35c4-02.jpg"><p class="MultiMediaCaption">Figure 1. Mean (Â±SD) Steady-State Plasma Amprenavir Concentrations and Mean IC<span class="Sub">50 </span>Values Against HIV from Protease Inhibitor-Naive Patients (in the Absence of Human Serum)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7d771d81-cfb1-493f-a319-9f5c8dcade66"></a><a name="section-11.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Absorption and Bioavailability</span></p>
<p> After administration of a single dose of LEXIVA to HIV-1-infected patients, the time to peak amprenavir concentration (T<span class="Sub">max</span>) occurred between 1.5 and 4Â hours (median 2.5Â hours). The absolute oral bioavailability of amprenavir after administration of LEXIVA in humans has not been established.</p>
<p> After administration of a single 1,400-mg dose in the fasted state, LEXIVA Oral Suspension (50Â mg/mL) and LEXIVA Tablets (700Â mg) provided similar amprenavir exposures (AUC), however, the C<span class="Sub">max</span> of amprenavir after administration of the suspension formulation was 14.5% higher compared with the tablet.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9845b3bd-d21b-4534-a53a-06d24c8fd5ba"></a><a name="section-11.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Effects of Food on Oral Absorption</span></p>
<p>Administration of a single 1,400-mg dose of LEXIVA Tablets in the fed state (standardized high-fat meal: 967Â kcal, 67Â grams fat, 33Â grams protein, 58Â grams carbohydrate) compared with the fasted state was associated with no significant changes in amprenavir C<span class="Sub">max</span>, T<span class="Sub">max</span>, or AUC<span class="Sub">0-</span>âˆž <span class="Italics">[see Dosage and Administration (2)]</span>.</p>
<p> Administration of a single 1,400-mg dose of LEXIVA Oral Suspension in the fed state (standardized high-fat meal: 967Â kcal, 67Â grams fat, 33Â grams protein, 58Â grams carbohydrate) compared with the fasted state was associated with a 46% reduction in C<span class="Sub">max</span>, a 0.72-hour delay in T<span class="Sub">max</span>, and a 28% reduction in amprenavir AUC<span class="Sub">0-</span>âˆž.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b40ddba9-d84b-4d37-86a2-e0845276de78"></a><a name="section-11.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Distribution</span></p>
<p>InÂ vitro, amprenavir is approximately 90% bound to plasma proteins, primarily to alpha<span class="Sub">1</span>-acid glycoprotein. InÂ vitro, concentration-dependent binding was observed over the concentration range of 1 to 10Â mcg/mL, with decreased binding at higher concentrations. The partitioning of amprenavir into erythrocytes is low, but increases as amprenavir concentrations increase, reflecting the higher amount of unbound drug at higher concentrations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e84ecd78-8d8a-4877-99c6-13e74e45f01c"></a><a name="section-11.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Metabolism</span></p>
<p> After oral administration, fosamprenavir is rapidly and almost completely hydrolyzed to amprenavir and <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">inorganic phosphate</span> prior to reaching the systemic circulation. This occurs in the gut epithelium during absorption. Amprenavir is metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system. The 2Â major metabolites result from oxidation of the tetrahydrofuran and aniline moieties. Glucuronide conjugates of oxidized metabolites have been identified as minor metabolites in urine and feces.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e413d10-1f1f-48fd-87a4-62724c18afa2"></a><a name="section-11.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Elimination</span></p>
<p> Excretion of unchanged amprenavir in urine and feces is minimal. Unchanged amprenavir in urine accounts for approximately 1% of the dose; unchanged amprenavir was not detectable in feces. Approximately 14% and 75% of an administered single dose of <span class="Sup">14</span>C-amprenavir can be accounted for as metabolites in urine and feces, respectively. Two metabolites accounted for &gt;90% of the radiocarbon in fecal samples. The plasma elimination half-life of amprenavir is approximately 7.7Â hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f835f68d-124d-42e7-bf3b-7d9e7f0ded29"></a><a name="section-11.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Special Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a8c3d5d-88cd-4377-b4cc-d58b633e6be0"></a><a name="section-11.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The pharmacokinetics of amprenavir have been studied after the administration of LEXIVA in combination with ritonavir to adult HIV-1-infected patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Following 2Â weeks of dosing with LEXIVA plus ritonavir, the AUC of amprenavir was increased by approximately 22% in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, by approximately 70% in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, and by approximately 80% in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared with HIV-1-infected patients with normal hepatic function. Protein binding of amprenavir was decreased in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The unbound fraction at 2Â hours (approximate C<span class="Sub">max</span>) ranged between a decrease of -7% to an increase of 57% while the unbound fraction at the end of the dosing interval (C<span class="Sub">min</span>) increased from 50% to 102% <span class="Italics">[see Dosage and Administration (2.3)].</span></p>
<p>The pharmacokinetics of amprenavir have been studied after administration of amprenavir given as AGENERASE<span class="Sup">Â®</span> Capsules to adult patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Following administration of a single 600-mg oral dose the AUC of amprenavir was increased by approximately 2.5-fold in patients with moderate cirrhosis and by approximately 4.5-fold in patients with severe cirrhosis compared with healthy volunteers <span class="Italics">[see Dosage and Administration (2.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0722352-3207-4d48-8056-181b22939dcd"></a><a name="section-11.10"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The impact of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on amprenavir elimination in adult patients has not been studied. The renal elimination of unchanged amprenavir represents approximately 1% of the administered dose; therefore, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not expected to significantly impact the elimination of amprenavir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ea681cb-b599-4dca-a047-aa467252da98"></a><a name="section-11.11"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Pediatric Patients</span></p>
<p> The pharmacokinetics of amprenavir after administration of LEXIVA Oral Suspension and LEXIVA Tablets, with or without ritonavir, have been evaluated in 124Â patients 2 to 18Â years of age. Pharmacokinetic parameters for LEXIVA administered with food and with or without ritonavir in this patient population are provided in Tables 8 and 9 below. </p>
<a name="id_c07bb10f-e123-48ad-a133-3cae47d47395"></a><table width="0.000">
<caption><span>Table 8. Geometric Mean (95% CI) Steady-State Plasma Amprenavir Pharmacokinetic Parameters in Pediatric Patients Receiving LEXIVA 30Â mg/kg Twice Daily</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" rowspan="2" valign="top"><p class="First">Parameter</p></td>
<td align="center" colspan="2" rowspan="1" valign="top"><p class="First">2 to 5Â Years</p></td>
</tr>
<tr>
<td align="center" rowspan="1" valign="top"><p class="First">n</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">LEXIVA 30Â mg/kg b.i.d.</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top">
<p class="First">AUC<span class="Sub">(24)</span></p>
<p>(mcgâ€¢hr/mL)</p>
</td>
<td align="center" rowspan="1" valign="top"><p class="First">8</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">31.4</p>
<p>(13.7, 72.4)</p>
</td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">C<span class="Sub">max </span>(mcg/mL)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">8</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">5.00</p>
<p>(1.95, 12.8)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" rowspan="1" valign="top"><p class="First">C<span class="Sub">min</span> (mcg/mL)</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">17</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top">
<p class="First">0.454</p>
<p>(0.342, 0.604)</p>
</td>
</tr>
</tbody>
</table>
<a name="id_f22a3bf3-d288-47a2-8c12-84cc6d95f477"></a><table width="0.000">
<caption><span>Table 9. Geometric Mean (95% CI) Steady-State Plasma Amprenavir Pharmacokinetic Parameters in Pediatric and Adolescent Patients Receiving LEXIVA Plus Ritonavir Twice Daily </span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" rowspan="2" valign="top"><p class="First">Parameter</p></td>
<td class="Toprule" align="center" colspan="2" rowspan="1" valign="top"><p class="First">6 to 11Â Years</p></td>
<td align="center" colspan="2" rowspan="1" valign="top"><p class="First">12 to 18Â Years</p></td>
</tr>
<tr>
<td align="center" rowspan="1" valign="top"><p class="First">n</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">LEXIVA 18Â mg/kg plus</p>
<p>Ritonavir 3Â mg/kg b.i.d.</p>
</td>
<td align="center" rowspan="1" valign="top"><p class="First">n</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">LEXIVA 700Â mg plus Ritonavir 100Â mg b.i.d.</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">AUC<span class="Sub">(0-24) </span>(mcgâ€¢hr/mL)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">9</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">93.4</p>
<p>(67.8, 129)</p>
</td>
<td align="center" rowspan="1" valign="top"><p class="First">8</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">58.8</p>
<p>(38.8, 89.0)</p>
</td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">C<span class="Sub">max </span>(mcg/mL)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">9</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">6.07</p>
<p>(4.40, 8.38)</p>
</td>
<td align="center" rowspan="1" valign="top"><p class="First">8</p></td>
<td align="center" rowspan="1" valign="top">
<p class="First">4.33</p>
<p>(2.82, 6.65)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" rowspan="1" valign="top"><p class="First">C<span class="Sub">min</span> (mcg/mL)</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">17</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top">
<p class="First">2.69</p>
<p>(2.15, 3.36)</p>
</td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">24</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top">
<p class="First">1.61</p>
<p>(1.21, 2.15)</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ceebb66-dc5f-4da2-a277-1d4c3eca4883"></a><a name="section-11.12"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Geriatric Patients</span></p>
<p>The pharmacokinetics of amprenavir after administration of LEXIVA to patients over 65Â years of age have not been studied <span class="Italics">[see Use in Specific Populations (8.5)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d7e7263-b02f-4641-bdec-92b45ab2bb6e"></a><a name="section-11.13"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Gender</span></p>
<p> The pharmacokinetics of amprenavir after administration of LEXIVA do not differ between males and females. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f31d4bf5-ff5b-4a65-a690-bcd0b5eb31fc"></a><a name="section-11.14"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Race</span></p>
<p> The pharmacokinetics of amprenavir after administration of LEXIVA do not differ between blacks and non-blacks. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_778a29cf-a977-4020-8cb6-f9af98d82b4d"></a><a name="section-11.15"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Drug Interactions</span></p>
<p><span class="Italics">[See Contraindications (4), Warnings and Precautions (5.1), Drug Interactions (7)</span>.<span class="Italics">] </span></p>
<p> Amprenavir, the active metabolite of fosamprenavir, is metabolized in the liver by the cytochrome P450 enzyme system. Amprenavir inhibits CYP3A4. Data also suggest that amprenavir induces CYP3A4. Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4. Amprenavir does not inhibit CYP2D6, CYP1A2, CYP2C9, CYP2C19, CYP2E1, or uridine glucuronosyltransferase (UDPGT).</p>
<p> Drug interaction studies were performed with LEXIVA and other drugs likely to be coadministered or drugs commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span>. The effects of coadministration on AUC, C<span class="Sub">max</span>, and C<span class="Sub">min</span> values are summarized in Table 10 (effect of other drugs on amprenavir) and Table 12 (effect of LEXIVA on other drugs). In addition, since LEXIVA delivers comparable amprenavir plasma concentrations as AGENERASE, drug interaction data derived from studies with AGENERASE are provided in Tables 11 and 13. For information regarding clinical recommendations, <span class="Italics">see Drug Interactions (7)</span>.</p>
<a name="id_9b65c2ec-f295-4af6-8f18-f1577a3f649f"></a><table border="single" width="627.000">
<caption><span>Table 10. Drug Interactions: Pharmacokinetic Parameters for Amprenavir After Administration of LEXIVA in the Presence of the Coadministered Drug(s) </span></caption>
<col width="20.7%">
<col width="17.9%">
<col width="7.0%">
<col width="17.5%">
<col width="17.5%">
<col width="19.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<p class="First">Coadministered Drug(s)</p>
and Dose(s)</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First">Dose of <span class="Bold">LEXIVA</span><span class="Sup">a</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">n</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">% Change in<span class="Bold"> Amprenavir</span> Pharmacokinetic Parameters (90% CI)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">C<span class="Sub">max</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">AUC</td>
<td class="Botrule Rrule" align="center" valign="top">C<span class="Sub">min</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Antacid (MAALOX TC<span class="Sup">Â®</span>) </p>
30 mL single dose </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400Â mg </p>
single dose</td>
<td class="Botrule Rrule" align="center" valign="top">30</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“35</p>
(â†“24 to â†“42)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“18</p>
(â†“9 to â†“26)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘14</p>
(â†“7 to â†‘39)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Atazanavir</p>
<p>300Â mg q.d. for 10Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
<p>plus ritonavir 100Â mg b.i.d. </p>
for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">22</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Atorvastatin</p>
10Â mg q.d. for 4Â days </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400Â mg b.i.d. </p>
for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“18</p>
(â†“34 to â†‘1)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“27</p>
(â†“41 to â†“12)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“12</p>
(â†“27 to â†“6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Atorvastatin</p>
10Â mg q.d. for 4Â days </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
<p>plus ritonavir 100Â mg b.i.d. </p>
for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Efavirenz </p>
600Â mg q.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400Â mg q.d.</p>
<p>plus ritonavir </p>
<p>200Â mg q.d. for</p>
2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“13</p>
(â†“30 to â†‘7)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“36</p>
(â†“8 to â†“56)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Efavirenz </p>
<p>600Â mg q.d. plus additional</p>
<p> ritonavir 100Â mg q.d. for </p>
2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400Â mg q.d.</p>
<p>plus ritonavir</p>
<p>200Â mg q.d. for</p>
2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘18</p>
(â†‘1 to â†‘38)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘11</p>
(0 to â†‘24)</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Efavirenz </p>
600Â mg q.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir</p>
<p>100Â mg b.i.d. for</p>
2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“17</p>
(â†“4 to â†“29)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Esomeprazole </p>
20Â mg q.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">1,400Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">25</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Esomeprazole </p>
20Â mg q.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir</p>
<p>100Â mg b.i.d. for</p>
2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">23</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">EthinylÂ estradiol/norethin-drone</p>
<p>0.035Â mg/0.5Â mg q.d. for 21Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
<p>plus ritonavir<span class="Sup">b</span></p>
<p>100Â mg b.i.d. </p>
for 21Â days</td>
<td class="Botrule Rrule" align="center" valign="top">25</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”<span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”<span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”<span class="Sup">c</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Ketoconazole<span class="Sup">d</span></p>
<p>200Â mg q.d. for 4Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir</p>
<p>100Â mg b.i.d. for </p>
4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Lopinavir/ritonavir</p>
533Â mg/133Â mg b.i.d.</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400 mg b.i.d. </p>
for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">â†“13<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“26<span class="Sup">e</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“42<span class="Sup">e</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Lopinavir/ritonavir </p>
<p>400Â mg/100Â mg b.i.d. for </p>
2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir</p>
100Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“58</p>
(â†“42 to â†“70)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“63</p>
(â†“51 to â†“72)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“65</p>
(â†“54 to â†“73)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Methadone</p>
<p>70 to 120Â mg q.d. for 2Â weeks</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir</p>
100Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">19</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">c</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Nevirapine </p>
200Â mg b.i.d. for 2Â weeks<span class="Sup">f</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1,400Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“25</p>
(â†“37 to â†“10)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“33</p>
(â†“45 to â†“20)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“35</p>
(â†“50 to â†“15)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Nevirapine </p>
200Â mg b.i.d. for 2Â weeks<span class="Sup">f</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
plus ritonavir 100Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“11</p>
(â†“23 to â†‘3)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“19</p>
(â†“32 to â†“4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Phenytoin</p>
<p>300Â mg q.d. for 10Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
plus ritonavir 100Â mg b.i.d. for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘20</p>
(â†‘8 to â†‘34)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘19</p>
(â†‘6 to â†‘33)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Ranitidine </p>
<p>300Â mg single dose</p>
(administered 1Â hour before fosamprenavir)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400Â mg</p>
single dose</td>
<td class="Botrule Rrule" align="center" valign="top">30</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“51</p>
(â†“43 to â†“58)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“30</p>
(â†“22 to â†“37)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†”</p>
 (â†“19 to â†‘21)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Rifabutin</p>
150Â mg q.o.d. for 2Â weeks </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
plus ritonavir 100Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘36<span class="Sup">c</span></p>
(â†‘18 to â†‘55)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘35<span class="Sup">c</span></p>
(â†‘17 to â†‘56)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘17<span class="Sup">c</span></p>
(â†“1 to â†‘39)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Tenofovir </p>
<p>300Â mg q.d. for 4 to 48Â weeks</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir 100Â mg b.i.d. for </p>
4 to 48Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">45</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">g</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Tenofovir </p>
<p>300Â mg q.d. for 4 to 48Â weeks</p>
</td>
<td class="Rrule" align="center" valign="top">
<p class="First">1,400Â mg q.d.</p>
<p>plus ritonavir</p>
<p>200Â mg q.d. for</p>
4 to 48Â weeks</td>
<td class="Rrule" align="center" valign="top">60</td>
<td class="Rrule" align="center" valign="top">NA</td>
<td class="Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">g</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Concomitant medication is also shown in this column where appropriate. </p>
<p><span class="Sup">b </span>Ritonavir C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> increased by 63%, 45%, and 13%, respectively, compared with historical control. </p>
<p><span class="Sup">c </span>Compared with historical control.</p>
<p><span class="Sup">d </span>Patients were receiving LEXIVA/ritonavir for 10Â days prior to the 4-day treatment period with both ketoconazole and LEXIVA/ritonavir.</p>
<p><span class="Sup">e </span>Compared with LEXIVA 700Â mg/ritonavir 100Â mg b.i.d. for 2Â weeks.</p>
<p><span class="Sup">f </span>Patients were receiving nevirapine for at least 12Â weeks prior to study.</p>
<p><span class="Sup">g </span>Compared with parallel control group.</p>
<p>â†‘= Increase; â†“= Decrease; â†” = No change (â†‘or â†“â‰¤10%), NAÂ =Â Not applicable.</p>
<a name="id_5074ab43-2ea9-4e25-80d2-3317f933eaad"></a><table border="single" width="664.000">
<caption><span>Table 11. Drug Interactions: Pharmacokinetic Parameters for Amprenavir After Administration of AGENERASE in the Presence of the Coadministered Drug(s) </span></caption>
<col width="20.9%">
<col width="14.6%">
<col width="7.4%">
<col width="17.3%">
<col width="18.2%">
<col width="21.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<p class="First">Coadministered Drug(s)</p>
and Dose(s)</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First">Dose of <span class="Bold">AGENERASE</span><span class="Sup">a</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First">n</p></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top"><p class="First">% Change in<span class="Bold"> Amprenavir </span>Pharmacokinetic Parameters (90% CI)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">C<span class="Sub">max</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">AUC</td>
<td class="Botrule Rrule" align="center" valign="top">C<span class="Sub">min</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Abacavir </p>
300Â mg b.i.d. for 2 to 3Â weeks </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">900Â mg b.i.d. </p>
for 2 to 3Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Clarithromycin </p>
500Â mg b.i.d. for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘15</p>
(â†‘1 to â†‘31)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘18</p>
(â†‘8 to â†‘29)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘39</p>
(â†‘31 to â†‘47)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Delavirdine</p>
600Â mg b.i.d. for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">600Â mg b.i.d. </p>
for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘40<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘130<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘125<span class="Sup">b</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Ethinyl estradiol/norethindrone</p>
0.035Â mg/1Â mg for 1Â cycle</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 28Â days</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“22</p>
(â†“35 to â†“8)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“20</p>
(â†“41 to â†‘8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Indinavir </p>
<p>800Â mg t.i.d. for 2Â weeks </p>
(fasted)</td>
<td class="Botrule Rrule" align="center" valign="top">750 or 800Â mg t.i.d. for 2Â weeks (fasted)</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘18</p>
(â†‘13 to â†‘58)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘33</p>
(â†‘2 to â†‘73)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘25</p>
(â†“27 to â†‘116)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Ketoconazole </p>
400Â mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg</p>
single dose</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“16</p>
(â†“25 to â†“6)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘31</p>
(â†‘20 to â†‘42)</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Lamivudine </p>
150Â mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">600Â mg</p>
single dose</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Methadone</p>
<p>44 to 100Â mg q.d. for </p>
&gt;30Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d. </p>
for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">â†“27<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“30<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“25<span class="Sup">c</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Nelfinavir </p>
<p>750Â mg t.i.d. for 2Â weeks </p>
(fed)</td>
<td class="Botrule Rrule" align="center" valign="top">750 or 800Â mg t.i.d. for 2Â weeks (fed)</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“14</p>
(â†“38 to â†‘20)</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘189</p>
(â†‘52 to â†‘448)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Rifabutin </p>
300Â mg q.d. for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“15</p>
(â†“28 to 0)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“15</p>
(â†“38 to â†‘17)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Rifampin </p>
300Â mg q.d. for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“70</p>
(â†“76 to â†“62)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“82</p>
(â†“84 to â†“78)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“92</p>
(â†“95 to â†“89)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Saquinavir </p>
<p>800Â mg t.i.d. for 2Â weeks </p>
(fed)</td>
<td class="Botrule Rrule" align="center" valign="top">750 or 800Â mg t.i.d. for 2Â weeks (fed)</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“37</p>
(â†“54 to â†“14)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“32</p>
(â†“49 to â†“9)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“14</p>
(â†“52 to â†‘54)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Zidovudine </p>
300Â mg single dose</td>
<td class="Rrule" align="center" valign="top">
<p class="First">600Â mg</p>
single dose</td>
<td class="Rrule" align="center" valign="top">12</td>
<td class="Rrule" align="center" valign="top">â†”</td>
<td class="Rrule" align="center" valign="top">
<p class="First">â†‘13</p>
(â†“2 to â†‘31)</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Compared with parallel control group.</p>
<p><span class="Sup">b </span>Median percent change; confidence interval not reported.</p>
<p><span class="Sup">c </span>Compared with historical data.</p>
<p>â†‘ = Increase; â†“ = Decrease; â†”= No change (â†‘or â†“&lt;10%); NA = C<span class="Sub">min</span> not calculated for single-dose study.</p>
<a name="id_10273971-631f-4f4f-b375-90030f295137"></a><table border="single" width="648.000">
<caption><span>Table 12. Drug Interactions: Pharmacokinetic Parameters for Coadministered Drug in the Presence of Amprenavir After Administration of LEXIVA </span></caption>
<col width="19.4%">
<col width="16.2%">
<col width="8.5%">
<col width="17.0%">
<col width="17.7%">
<col width="21.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<p class="First">Coadministered Drug(s)</p>
and Dose(s)</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">Dose of <span class="Bold">LEXIVA</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top"><p class="First">n</p></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">% Change inÂ  Pharmacokinetic Parameters of <span class="Bold">Coadministered Drug </span>(90% CI)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">C<span class="Sub">max</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">AUC</td>
<td class="Botrule Rrule" align="center" valign="top">C<span class="Sub">min</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Atazanavir</p>
300Â mg q.d. for 10Â days<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
<p>plus ritonavir 100Â mg b.i.d. </p>
for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">21</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“24</p>
(â†“39 to â†“6)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“22</p>
(â†“34 to â†“9)</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Atorvastatin</p>
10Â mg q.d. for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400Â mg b.i.d.</p>
for 2 weeks</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘304</p>
(â†‘205 to â†‘437)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘130</p>
(â†‘100 to â†‘164)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“10</p>
(â†“27 to â†‘12)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Atorvastatin</p>
10Â mg q.d. for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir 100Â mg b.i.d. </p>
for 2 weeks</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘184</p>
(â†‘126 to â†‘257)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘153</p>
(â†‘115 to â†‘199)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘73</p>
(â†‘45 to â†‘108)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Esomeprazole </p>
20Â mg q.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">1,400Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">25</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘55</p>
(â†‘39 to â†‘73)</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Esomeprazole </p>
20Â mg q.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir</p>
100Â mg b.i.d. for<br>2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">23</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Ethinyl estradiol<span class="Sup">c</span></p>
<p>0.035Â mg q.d. for 21Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
<p>plus ritonavir</p>
<p>100Â mg b.i.d. </p>
for 21Â days</td>
<td class="Botrule Rrule" align="center" valign="top">25</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“28</p>
(â†“21 to â†“35)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“37</p>
(â†“30 to â†“42)</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Ketoconazole<span class="Sup">d</span></p>
<p>200Â mg q.d. for 4Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
<p>plus ritonavir</p>
<p>100Â mg b.i.d. for </p>
4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘25</p>
<p>(â†‘0 to â†‘56)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘169</p>
(â†‘108 to â†‘248)</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Lopinavir/ritonavir<span class="Sup">e</span></p>
<p>533Â mg/133Â mg b.i.d. for </p>
2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400Â mg b.i.d.</p>
for 2 weeks</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">f</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">f</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">f</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Lopinavir/ritonavir<span class="Sup">e</span></p>
<p>400Â mg/100Â mg b.i.d. for</p>
 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
plus ritonavir 100Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">18</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘30</p>
(â†“15 to â†‘47)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘37</p>
(â†“20 to â†‘55)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘52</p>
(â†“28 to â†‘82)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="4" valign="top">
<p class="First">Methadone</p>
<p>70 to 120Â mg q.d. for </p>
<p>2Â weeks</p>
</td>
<td class="Botrule Rrule" align="center" rowspan="4" valign="top">
<p class="First">700Â mg b.i.d.</p>
plus ritonavir 100Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" rowspan="4" valign="top">19</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">R-Methadone (active)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">â†“21<span class="Sup">g</span></p>
(â†“30 to â†“12)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“18<span class="Sup">g</span></p>
(â†“27 to â†“8)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“11<span class="Sup">g</span></p>
(â†“21 to â†‘1)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top">S-Methadone (inactive)</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">â†“43<span class="Sup">g</span></p>
(â†“49 to â†“37)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“43<span class="Sup">g</span></p>
(â†“50 to â†“36)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“41<span class="Sup">g</span></p>
(â†“49 to â†“31)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Nevirapine </p>
200Â mg b.i.d. for 2Â weeks<span class="Sup">h</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,400Â mg b.i.d.</p>
for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘25</p>
(â†‘14 to â†‘37)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘29</p>
(â†‘19 to â†‘40)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘34</p>
(â†‘20 to â†‘49)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Nevirapine </p>
200Â mg b.i.d. for 2Â weeks<span class="Sup"> h</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">700Â mg b.i.d. plus ritonavir 100Â mg b.i.d. for 2Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘13</p>
(â†‘3 to â†‘24)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘14</p>
(â†‘5 to â†‘24)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘22</p>
(â†‘9 to â†‘35)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Norethindrone<span class="Sup">c</span></p>
<p>0.5Â mg q.d. for 21Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
<p>plus ritonavir</p>
<p>100Â mg b.i.d. </p>
for 21Â days</td>
<td class="Botrule Rrule" align="center" valign="top">25</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“38</p>
(â†“32 to â†“44)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“34</p>
(â†“30 to â†“37)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“26</p>
(â†“20 to â†“32)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Phenytoin</p>
<p>300Â mg q.d. for 10Â days</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d. </p>
plus ritonavir 100Â mg b.i.d. for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“20</p>
(â†“12 to â†“27)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“22</p>
(â†“17 to â†“27)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“29</p>
(â†“23 to â†“34)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Rifabutin</p>
<p>150Â mg every other day for 2Â weeks<span class="Sup"> c</span></p>
<p>(25-O-desacetylrifabutin</p>
<p>metabolite)</p>
<p>Rifabutin + 25-O-</p>
<p>desacetylrifabutin</p>
metabolite</td>
<td class="Rrule" align="center" valign="top">
<p class="First">700Â mg b.i.d.</p>
plus ritonavir 100Â mg b.i.d. for 2Â weeks</td>
<td class="Rrule" align="center" valign="top">15</td>
<td class="Rrule" align="center" valign="top">
<p class="First">â†“14</p>
<p>(â†“28 to â†‘4)</p>
<p>â†‘579</p>
<p>(â†‘479 to â†‘698)</p>
NA</td>
<td class="Rrule" align="center" valign="top">
<p class="First">â†”</p>
<p>â†‘1,120</p>
<p>(â†‘965 to â†‘1,300)</p>
<p>â†‘64</p>
(â†‘46 to â†‘84)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘28</p>
<p>(â†‘12 to â†‘46)</p>
<p>â†‘2,510</p>
<p>(â†‘1,910 to â†‘3,300)</p>
NA</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Concomitant medication is also shown in this column where appropriate.</p>
<p><span class="Sup">b </span>Comparison arm of atazanavir 300Â mg q.d. plus ritonavir 100Â mg q.d. for 10Â days.</p>
<p><span class="Sup">c</span> Administered as a combination oral contraceptive tablet: ethinyl estradiol 0.035Â mg/norethindrone 0.5Â mg.</p>
<p><span class="Sup">d </span>Patients were receiving LEXIVA/ritonavir for 10Â days prior to the 4-day treatment period with both ketoconazole and LEXIVA/ritonavir.</p>
<p><span class="Sup">e </span>Data represent lopinavir concentrations. </p>
<p><span class="Sup">f </span>Compared with lopinavir 400Â mg/ritonavir 100Â mg b.i.d. for 2Â weeks.</p>
<p><span class="Sup">g </span>Dose normalized to methadone 100Â mg. The unbound concentration of the active moiety, R-methadone, was unchanged.</p>
<p><span class="Sup">h </span>Patients were receiving nevirapine for at least 12Â weeks prior to study.<span class="Sup">â€ â€ </span>Comparison arm of rifabutin 300Â mg q.d. for 2Â weeks. AUC is AUC<span class="Sub">(0-48Â hr)</span>.</p>
<p>â†‘= Increase; â†“= Decrease; â†” = No change (â†‘or â†“&lt;10%); ND = Interaction cannot be determined as C<span class="Sub">min</span> was below the lower limit of quantitation. </p>
<a name="id_a69fe5aa-9085-41b4-b52e-63defc31fbff"></a><table border="single" width="658.000">
<caption><span>Table 13. Drug Interactions: Pharmacokinetic Parameters for Coadministered Drug in the Presence of Amprenavir After Administration of AGENERASE</span></caption>
<col width="21.9%">
<col width="14.0%">
<col width="7.4%">
<col width="18.4%">
<col width="19.1%">
<col width="19.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<p class="First">Coadministered</p>
Drug(s) and Dose(s)</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">Dose of <span class="Bold">AGENERASE</span>
</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">n</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">% Change inÂ  Pharmacokinetic Parameters of <span class="Bold">Coadministered Drug </span>(90% CI)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">C<span class="Sub">max</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">AUC</td>
<td class="Botrule Rrule" align="center" valign="top">C<span class="Sub">min</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Abacavir </p>
300Â mg b.i.d. for 2 to 3Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">900Â mg b.i.d </p>
for 2 to 3Â weeks</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Clarithromycin </p>
500Â mg b.i.d. for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“10</p>
(â†“24 to â†‘7)</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Delavirdine</p>
600Â mg b.i.d. for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">600 mg b.i.d. </p>
for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">â†“47<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“61<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“88<span class="Sup">b</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Ethinyl estradiol</p>
0.035Â mg for 1Â cycle</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 28Â days</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”<br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘32</p>
(â†“3 to â†‘79)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Indinavir </p>
800Â mg t.i.d. for 2Â weeks (fasted)</td>
<td class="Botrule Rrule" align="center" valign="top">750 mg or 800Â mg t.i.d. for 2Â weeks (fasted)</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">â†“22<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“38<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“27<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Ketoconazole </p>
400Â mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg</p>
single dose</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘19</p>
(â†‘8 to â†‘33)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘44</p>
(â†‘31 to â†‘59)</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Lamivudine </p>
150Â mg single dose</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">600Â mg</p>
single dose</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="4" valign="top">
<p class="First">Methadone</p>
<p>44 to 100Â mg q.d. for </p>
&gt;30Â days</td>
<td class="Botrule Rrule" align="center" rowspan="4" valign="top">
<p class="First">1,200Â mg b.i.d. </p>
for 10 days</td>
<td class="Botrule Rrule" align="center" rowspan="4" valign="top">16</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">R-Methadone (active)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">â†“25</p>
(â†“32 to â†“18)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“13</p>
(â†“21 to â†“5)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“21</p>
(â†“32 to â†“9)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top">S-Methadone (inactive)</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">â†“48</p>
(â†“55 to â†“40)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“40</p>
(â†“46 to â†“32)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†“53</p>
(â†“60 to â†“43)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Nelfinavir </p>
<p>750Â mg t.i.d. for 2Â weeks (fed)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">750 mg or 800Â mg t.i.d. for 2Â weeks (fed)</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘12<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘15<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘14<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Norethindrone</p>
1Â mg for 1Â cycle</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 28Â days</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘18</p>
(â†‘1 to â†‘38)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘45</p>
(â†‘13 to â†‘88)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Rifabutin </p>
300Â mg q.d. for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 10Â days</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘119</p>
(â†‘82 to â†‘164)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘193</p>
(â†‘156 to â†‘235)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">â†‘271</p>
(â†‘171 to â†‘409)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Rifampin </p>
300Â mg q.d. for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1,200Â mg b.i.d.</p>
for 4Â days</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">â†”</td>
<td class="Botrule Rrule" align="center" valign="top">ND</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Saquinavir </p>
<p>800Â mg t.i.d. for 2Â weeks (fed)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">750Â mg or 800Â mg t.i.d. for 2Â weeks (fed)</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">â†‘21<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“19<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">â†“48<span class="Sup">a</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Zidovudine </p>
300Â mg single dose</td>
<td class="Rrule" align="center" valign="top">
<p class="First">600Â mg</p>
single dose</td>
<td class="Rrule" align="center" valign="top">12</td>
<td class="Rrule" align="center" valign="top">
<p class="First">â†‘40</p>
(â†‘14 to â†‘71)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">â†‘31</p>
(â†‘19 to â†‘45)</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Compared with historical data. </p>
<p><span class="Sup">b</span> Median percent change; confidence interval not reported.</p>
<p>â†‘ = Increase; â†“ = Decrease; â†”= No change (â†‘or â†“&lt;10%); NA = C<span class="Sub">min</span> not calculated for single-dose study; ND = Interaction cannot be determined as C<span class="Sub">min</span> was below the lower limit of quantitation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_295f0648-0829-42c4-b58b-fb1504be5801"></a><a name="section-11.16"></a><p></p>
<h2>
<span class="Bold">12.4</span> Microbiology</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_922b0911-1bd7-4e83-853a-1e4e21dfaccc"></a><a name="section-11.17"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Mechanism of Action</span></p>
<p> Fosamprenavir is a prodrug that is rapidly hydrolyzed to amprenavir by cellular phosphatases in the gut epithelium as it is absorbed. Amprenavir is an inhibitor of HIV-1 protease. Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral Gag and Gag-Pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75a32589-f99a-4ecf-8cd2-8324d3f46ccd"></a><a name="section-11.18"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Antiviral Activity</span></p>
<p> Fosamprenavir has little or no antiviral activity inÂ vitro. The inÂ vitro antiviral activity of amprenavir was evaluated against HIV-1 IIIB in both acutely and chronically infected lymphoblastic cell lines (MT-4, CEM-CCRF, H9) and in peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. The 50% effective concentration (EC<span class="Sub">50</span>) of amprenavir ranged from 0.012 to 0.08Â Î¼M in acutely infected cells and was 0.41Â Î¼M in chronically infected cells (1Â Î¼MÂ =Â 0.50Â mcg/mL). The median EC<span class="Sub">50</span> value of amprenavir against HIV-1 isolates from clades A to G was 0.00095Â ÂµM in peripheral blood mononuclear cells (PBMCs). Similarly, the EC<span class="Sub">50</span> values for amprenavir against monocytes/macrophage tropic HIV-1 isolates (clade B) ranged from 0.003 to 0.075Â ÂµM in monocyte/macrophage cultures. The EC<span class="Sub">50</span> values of amprenavir against HIV-2 isolates grown in PBMCs were higher than those for HIV-1 isolates, and ranged from 0.003 to 0.11Â ÂµM. Amprenavir exhibited synergistic antiâ€“HIV-1 activity in combination with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir, didanosine, lamivudine, stavudine, tenofovir, and zidovudine; the non-nucleoside reverse transcriptase inhibitors (NNRTIs) delavirdine and efavirenz; and the protease inhibitors atazanavir and saquinavir. Amprenavir exhibited additive antiâ€“HIV-1 activity in combination with the NNRTI nevirapine, the protease inhibitors indinavir, lopinavir, nelfinavir, and ritonavir; and the fusion inhibitor enfuvirtide. These drug combinations have not been adequately studied in humans. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88e290ae-9a3b-4384-9cdb-46cc8e0caa45"></a><a name="section-11.19"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Resistance</span></p>
<p> HIV-1 isolates with decreased susceptibility to amprenavir have been selected inÂ vitro and obtained from patients treated with fosamprenavir. Genotypic analysis of isolates from treatment-naive patients failing amprenavir-containing regimens showed mutations in the HIV-1 protease gene resulting in amino acid substitutions primarily at positions V32I, M46I/L, I47V, I50V, I54L/M, and I84V, as well as mutations in the p7/p1 and p1/p6 Gag and Gag-Pol polyprotein precursor cleavage sites. Some of these amprenavir resistance-associated mutations have also been detected in HIV-1 isolates from antiretroviral-naive patients treated with LEXIVA. Of the 488Â antiretroviral-naive patients treated with LEXIVA 1,400Â mg twice daily or LEXIVA 1,400Â mg plus ritonavir 200Â mg once daily in studies APV30001 and APV30002, respectively, 61Â patients (29 receiving LEXIVA and 32 receiving LEXIVA/ritonavir) with virologic failure (plasma HIV-1 RNA &gt;1,000Â copies/mL on 2Â occasions on or after WeekÂ 12) were genotyped. Five of the 29Â antiretroviral-naive patients (17%) receiving LEXIVA without ritonavir in study APV30001 had evidence of genotypic resistance to amprenavir: I54L/M (nÂ =Â 2), I54LÂ +Â L33F (nÂ =Â 1), V32IÂ +Â I47V (nÂ =Â 1), and M46IÂ +Â I47V (nÂ =Â 1). No amprenavir resistance-associated mutations were detected in antiretroviral-naive patients treated with LEXIVA/ritonavir for 48Â weeks in study APV30002. However, the M46I and I50V mutations were detected in isolates from 1Â virologic failure patient receiving LEXIVA/ritonavir once daily at WeekÂ 160 (HIV-1 RNA &gt;500Â copies/mL). Upon retrospective analysis of stored samples using an ultrasensitive assay, these resistant mutants were traced back to WeekÂ 84 (76Â weeks prior to clinical virologic failure).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4749d796-b75e-42b1-a013-931bd2de745a"></a><a name="section-11.20"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Cross-Resistance</span></p>
<p> Varying degrees of cross-resistance among HIV-1 protease inhibitors have been observed. An association between virologic response at 48Â weeks (HIV-1 RNA level &lt;400Â copies/mL) and protease inhibitor-resistance mutations detected in baseline HIV-1 isolates from protease inhibitor-experienced patients receiving LEXIVA/ritonavir twice daily (nÂ =Â 88), or lopinavir/ritonavir twice daily (nÂ =Â 85) in study APV30003 is shown in Table 14. The majority of subjects had previously received either one (47%) or 2 protease inhibitors (36%), most commonly nelfinavir (57%) and indinavir (53%). Out of 102Â subjects with baseline phenotypes receiving twice-daily LEXIVA/ritonavir, 54% (nÂ =Â 55) had resistance to at least one protease inhibitor, with 98% (nÂ =Â 54) of those having resistance to nelfinavir. Out of 97Â subjects with baseline phenotypes in the lopinavir/ritonavir arm, 60% (nÂ =Â 58) had resistance to at least one protease inhibitor, with 97% (nÂ =Â 56) of those having resistance to nelfinavir.</p>
<a name="id_117affc0-3753-4982-ac53-09ead2c3af32"></a><table width="0.000">
<caption><span>Table 14. Responders at Study Week 48 by Presence of Baseline Protease Inhibitor Resistance-Associated Mutations<span class="Sup">a</span></span></caption>
<col>
<col>
<col>
<col>
<col>
<tfoot>
<tr><td align="left" colspan="5" rowspan="1" valign="top"><p class="First"><span class="Sup">a</span>Results should be interpreted with caution because the subgroups were small.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="5" rowspan="1" valign="top"><p class="First"><span class="Sup">b</span>Most patients had &gt;1 protease inhibitor resistance-associated mutation at baseline. </p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" rowspan="1" valign="top"><p class="First">PI-mutations<span class="Sup">b</span></p></td>
<td class="Toprule" align="center" colspan="2" rowspan="1" valign="top"><p class="First">LEXIVA/Ritonavir b.i.d. (nÂ =Â 88)</p></td>
<td align="center" colspan="2" rowspan="1" valign="top"><p class="First">Lopinavir/Ritonavir b.i.d. (nÂ =Â 85)</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">D30N</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">21/22</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">95%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">17/19</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">89%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">N88D/S</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">20/22</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">91%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">12/12</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">100%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">L90M</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">16/31</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">52%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">17/29</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">59%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">M46I/L</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">11/22</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">50%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">12/24</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">50%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">V82A/F/T/S</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2/9</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">22%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">6/17</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">35%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">I54V</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2/11</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">18%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">6/11</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">55%</p></td>
</tr>
<tr class="Last">
<td align="left" rowspan="1" valign="top"><p class="First">I84V</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1/6</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">17%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2/5</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">40%</p></td>
</tr>
</tbody>
</table>
<p> The virologic response based upon baseline phenotype was assessed. Baseline isolates from protease inhibitor-experienced patients responding to LEXIVA/ritonavir twice daily had a median shift in susceptibility to amprenavir relative to a standard wild-type reference <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of 0.7 (range: 0.1 to 5.4, nÂ =Â 62), and baseline isolates from individuals failing therapy had a median shift in susceptibility of 1.9 (range: 0.2 to 14, nÂ =Â 29). Because this was a select patient population, these data do not constitute definitive clinical susceptibility break points. Additional data are needed to determine clinically relevant break points for LEXIVA.</p>
<p> Isolates from 15 of the 20Â patients receiving twice-daily LEXIVA/ritonavir up to WeekÂ 48 and experiencing virologic failure/ongoing replication were subjected to genotypic analysis. The following amprenavir resistance-associated mutations were found either alone or in combination: V32I, M46I/L, I47V, I50V, I54L/M, and I84V. Isolates from 4 of the 16Â patients continuing to receive twice-daily LEXIVA/ritonavir up to WeekÂ 96 who experienced virologic failure underwent genotypic analysis. Isolates from 2Â patients contained amprenavir resistance-associated mutations: V32I, M46I, and I47V in 1Â isolate and I84V in the other. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_50e79600-e0fe-4a2b-95bb-d933c7c422fa"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_2008d8ba-a775-477c-8a9e-14dabb0cdd7f"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"> In long-term carcinogenicity studies, fosamprenavir was administered orally for up to 104Â weeks at doses of 250, 400, or 600Â mg/kg/day in mice and at doses of 300, 825, or 2,250Â mg/kg/day in rats. Exposures at these doses were 0.3- to 0.7-fold (mice) and 0.7- to 1.4-fold (rats) those in humans given 1,400Â mg twice daily of fosamprenavir alone, and 0.2- to 0.3-fold (mice) and 0.3- to 0.7-fold (rats) those in humans given 1,400Â mg once daily of fosamprenavir plus 200Â mg ritonavir once daily. Exposures in the carcinogenicity studies were 0.1- to 0.3-fold (mice) and 0.3- to 0.6-fold (rats) those in humans given 700Â mg of fosamprenavir plus 100Â mg ritonavir twice daily. There was an increase in <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and hepatocellular carcinomas at all doses in male mice and at 600Â mg/kg/day in female mice, and in <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> at all doses in male rats, and at 835Â mg/kg/day and 2,250Â mg/kg/day in female rats. The relevance of the hepatocellular findings in the rodents for humans is uncertain. Repeat dose studies with fosamprenavir in rats produced effects consistent with enzyme induction, which predisposes rats, but not humans, to thyroid neoplasms. In addition, in rats only there was an increase in interstitial cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> at 825Â mg/kg/day and 2,250Â mg/kg/day, and an increase in uterine endometrial adenocarcinoma at 2,250Â mg/kg/day. The incidence of endometrial findings was slightly increased over concurrent controls, but was within background range for female rats. The relevance of the uterine endometrial adenocarcinoma findings in rats for humans is uncertain. </p>
<p> Fosamprenavir was not mutagenic or genotoxic in a battery of inÂ vitro and inÂ vivo assays. These assays included bacterial reverse mutation (Ames), mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, rat micronucleus, and chromosome aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
<p> The effects of fosamprenavir on fertility and general reproductive performance were investigated in male (treated for 4Â weeks before mating) and female rats (treated for 2Â weeks before mating through postpartum dayÂ 6). Systemic exposures (AUC<span class="Sub">0-24 hr</span>) to amprenavir in these studies were 3 (males) to 4 (females) times higher than exposures in humans following administration of the MRHD of fosamprenavir alone or similar to those seen in humans following administration of fosamprenavir in combination with ritonavir. Fosamprenavir did not impair mating or fertility of male or female rats and did not affect the development and maturation of sperm from treated rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_27e9246d-6396-4815-9455-b563672f2168"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c21c799-da25-4264-8da6-35cecdf0af4e"></a><a name="section-13.1"></a><p></p>
<h2>
<span class="Bold">14.1</span> Therapy-Naive Adult Patients</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_59bffa49-16bb-4f95-8f88-451c313a9fb5"></a><a name="section-13.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Study APV30001</span></p>
<p> APV30001 was a randomized, open-label study, comparing treatment with LEXIVA Tablets (1,400Â mg twice daily) versus nelfinavir (1,250Â mg twice daily) in 249Â antiretroviral treatment-naive patients. Both groups of patients also received abacavir (300Â mg twice daily) and lamivudineÂ (150Â mg twice daily). </p>
<p> The mean age of the patients in this study was 37Â years (range: 17 to 70Â years), 69% of the patients were males, 20% were CDC Class C (AIDS), 24% were Caucasian, 32% were black, and 44% were Hispanic. At baseline, the median CD4+ cell count was 212Â cells/mm<span class="Sup">3</span> (range: 2 to 1,136Â cells/mm<span class="Sup">3</span>; 18% of patients had a CD4+ cell count of &lt;50Â cells/mm<span class="Sup">3</span> and 30% were in the range of 50 to &lt;200Â cells/mm<span class="Sup">3</span>). Baseline median HIV-1 RNA was 4.83Â log<span class="Sub">10Â </span>copies/mL (range: 1.69 to 7.41Â log<span class="Sub">10Â </span>copies/mL; 45% of patients had &gt;100,000Â copies/mL).</p>
<p> The outcomes of randomized treatment are provided in Table 15. </p>
<a name="id_cf98853a-76f2-4df5-85dd-e16635c4d948"></a><table width="0.000">
<caption><span>Table 15. Outcomes of Randomized Treatment Through Week 48 (APV30001) </span></caption>
<col>
<col>
<col>
<tfoot>
<tr><td align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">a</span> Patients achieved and maintained confirmed HIV-1 RNA &lt;400Â copies/mL (&lt;50Â copies/mL) through WeekÂ 48 (Roche AMPLICOR HIV-1 MONITOR Assay Version 1.5).</p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">b</span> Includes consent withdrawn, lost to follow up, protocol violations, those with missing data, and other reasons.</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" rowspan="1" valign="top">
<p class="First">Outcome</p>
<p>(Rebound or discontinuation = failure)</p>
</td>
<td class="Toprule" align="center" rowspan="1" valign="top">
<p class="First">LEXIVA</p>
<p>1,400Â mg b.i.d.</p>
<p>(nÂ =Â 166)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">Nelfinavir</p>
<p>1,250Â mg b.i.d.</p>
<p>(nÂ =Â 83)</p>
</td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Responder<span class="Sup">a</span></p></td>
<td align="center" rowspan="1" valign="top"><p class="First">66% (57%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">52% (42%)</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Virologic failure</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">19%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">32%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First"> Rebound</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">16%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">19%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First"> Never suppressed through WeekÂ 48</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">3%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">13%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Clinical progression</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td align="center" rowspan="1" valign="top"><p class="First">0%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Discontinued due to adverse reactions</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">4%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2%</p></td>
</tr>
<tr class="Last">
<td align="left" rowspan="1" valign="top"><p class="First">Discontinued due to other reasons<span class="Sup">b</span></p></td>
<td align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
</tr>
</tbody>
</table>
<p> Treatment response by viral load strata is shown in Table 16. </p>
<a name="id_20f8ccbe-8c80-415c-b643-171f009e3f5e"></a><table width="0.000">
<caption><span>Table 16. Proportions of Responders Through WeekÂ 48 by Screening Viral Load (APV30001)</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" rowspan="2" valign="top"><p class="First">Screening Viral Load HIV-1 RNA (copies/mL)</p></td>
<td class="Toprule" align="center" colspan="2" rowspan="1" valign="top">
<p class="First">LEXIVA </p>
<p>1,400Â mg b.i.d.</p>
</td>
<td align="center" colspan="2" rowspan="1" valign="top">
<p class="First">Nelfinavir </p>
<p>1,250Â mg b.i.d.</p>
</td>
</tr>
<tr>
<td align="center" rowspan="1" valign="top"><p class="First">&lt;400Â copies/mL</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">n</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">&lt;400Â copies/mL</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">n</p></td>
</tr>
<tr>
<td align="justify" rowspan="1" valign="top"><p class="First">â‰¤100,000</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">65%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">93</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">65%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">46</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="justify" rowspan="1" valign="top"><p class="First">&gt;100,000</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">67%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">73</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">36%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">37</p></td>
</tr>
</tbody>
</table>
<p> Through 48Â weeks of therapy, the median increases from baseline in CD4+ cell counts were 201Â cells/mm<span class="Sup">3 </span>in the group receiving LEXIVA and 216Â cells/mm<span class="Sup">3</span> in the nelfinavir group. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e297fa2b-9d63-4bb0-b1bb-1afaf710674c"></a><a name="section-13.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Study APV30002</span></p>
<p>APV30002 was a randomized, open-label study, comparing treatment with LEXIVA Tablets (1,400Â mg once daily) plus ritonavir (200Â mg once daily) versus nelfinavir (1,250Â mg twice daily) in 649Â treatment-naive patients. Both treatment groups also received abacavir (300Â mg twice daily) and lamivudineÂ (150Â mg twice daily). </p>
<p> The mean age of the patients in this study was 37Â years (range: 18 to 69Â years), 73% of the patients were males, 22% were CDC Class C, 53% were Caucasian, 36% were black, and 8% were Hispanic. At baseline, the median CD4+ cell count was 170Â cells/mm<span class="Sup">3</span> (range: 1 to 1,055Â cells/mm<span class="Sup">3</span>; 20% of patients had a CD4+ cell count of &lt;50Â cells/mm<span class="Sup">3 </span>and 35% were in the range of 50 to &lt;200Â cells/mm<span class="Sup">3</span>). Baseline median HIV-1 RNA was 4.81Â log<span class="Sub">10Â </span>copies/mL (range: 2.65 to 7.29Â log<span class="Sub">10Â </span>copies/mL; 43% of patients had &gt;100,000Â copies/mL). </p>
<p> The outcomes of randomized treatment are provided in Table 17. </p>
<a name="id_5784a8ee-4ef9-409e-b758-9a74d973c4ab"></a><table width="432.000">
<caption><span>Table 17. Outcomes of Randomized Treatment Through Week 48 (APV30002) </span></caption>
<col width="33.3%">
<col width="33.3%">
<col width="33.3%">
<tfoot>
<tr><td align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">a</span> Patients achieved and maintained confirmed HIV-1 RNA &lt;400Â copies/mL (&lt;50Â copies/mL) through WeekÂ 48 (Roche AMPLICOR HIV-1 MONITOR Assay Version 1.5).</p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">b</span> Includes consent withdrawn, lost to follow up, protocol violations, those with missing data, and other reasons.</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" rowspan="1" valign="top">
<p class="First">Outcome</p>
<p>(Rebound or discontinuation = failure)</p>
</td>
<td class="Toprule" align="center" rowspan="1" valign="top">
<p class="First">LEXIVA 1,400Â mg q.d./</p>
<p>Ritonavir 200Â mg q.d.</p>
<p>(nÂ =Â 322)</p>
</td>
<td align="center" rowspan="1" valign="top">
<p class="First">Nelfinavir</p>
<p>1,250Â mg b.i.d.</p>
<p>(nÂ =Â 327)</p>
</td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Responder<span class="Sup">a</span></p></td>
<td align="center" rowspan="1" valign="top"><p class="First">69% (58%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">68% (55%)</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Virologic failure</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">16%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Rebound</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">8%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Never suppressed through Week 48</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">8%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">0%</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">Discontinued due to adverse reactions</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">9%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
</tr>
<tr class="Last">
<td align="left" rowspan="1" valign="top"><p class="First">Discontinued due to other reasons<span class="Sup">b</span></p></td>
<td align="center" rowspan="1" valign="top"><p class="First">15%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
</tr>
</tbody>
</table>
<p> Treatment response by viral load strata is shown in Table 18. </p>
<a name="id_dd86d276-48cb-4933-ad07-867d07745329"></a><table width="0.000">
<caption><span>Table 18. Proportions of Responders Through Week 48 by Screening Viral Load (APV30002)</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" colspan="2" rowspan="1" valign="top"><p class="First">Screening Viral Load HIV-1 RNA</p></td>
<td class="Toprule" align="center" colspan="2" rowspan="1" valign="top"><p class="First">LEXIVA 1,400Â mg q.d./Ritonavir 200Â mg q.d.</p></td>
<td align="center" colspan="2" rowspan="1" valign="top">
<p class="First">Nelfinavir </p>
<p>1,250Â mg b.i.d.</p>
</td>
</tr>
<tr>
<td align="center" rowspan="1" valign="top"><p class="First">(copies/mL)</p></td>
<td align="center" colspan="2" rowspan="1" valign="top"><p class="First">&lt;400Â copies/mL</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">n</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">&lt;400Â copies/mL</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">n</p></td>
</tr>
<tr>
<td align="left" rowspan="1" valign="top"><p class="First">â‰¤100,000</p></td>
<td align="center" colspan="2" rowspan="1" valign="top"><p class="First">72%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">197</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">73%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">194</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" rowspan="1" valign="top"><p class="First">&gt;100,000</p></td>
<td class="Botrule" align="center" colspan="2" rowspan="1" valign="top"><p class="First">66%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">125</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">64%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">133</p></td>
</tr>
</tbody>
</table>
<p> Through 48Â weeks of therapy, the median increases from baseline in CD4+ cell counts were 203Â cells/mm<span class="Sup">3 </span>in the group receiving LEXIVA and 207Â cells/mm<span class="Sup">3</span> in the nelfinavir group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ddfeb490-3089-4862-bef9-39eaf539c0d9"></a><a name="section-13.4"></a><p></p>
<h2>
<span class="Bold">14.2</span> Protease Inhibitor-Experienced Adult Patients</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24e3629f-de15-425e-a5cc-99e771674353"></a><a name="section-13.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Study APV30003</span></p>
<p> APV30003 was a randomized, open-label, multicenter study comparing 2 different regimens of LEXIVA plus ritonavir (LEXIVA Tablets 700Â mg twice daily plus ritonavir 100Â mg twice daily or LEXIVA Tablets 1,400Â mg once daily plus ritonavir 200Â mg once daily) versus lopinavir/ritonavir (400Â mg/100Â mg twice daily) in 315Â patients who had experienced virologic failure to 1 or 2Â prior protease inhibitor-containing regimens. </p>
<p> The mean age of the patients in this study was 42Â years (range: 24Â to 72Â years), 85% were male, 33% were CDC Class C, 67% were Caucasian, 24% were black, and 9% were Hispanic. The median CD4+ cell count at baseline was 263Â cells/mm<span class="Sup">3</span> (range: 2 to 1,171Â cells/mm<span class="Sup">3</span>). Baseline median plasma HIV-1 RNA level was 4.14Â log<span class="Sub">10</span>Â copies/mL (range: 1.69 to 6.41Â log<span class="Sub">10</span>Â copies/mL). </p>
<p> The median durations of prior exposure to NRTIs were 257Â weeks for patients receiving LEXIVA/ritonavir twice daily (79% had â‰¥3 prior NRTIs) and 210Â weeks for patients receiving lopinavir/ritonavir (64% had â‰¥3 prior NRTIs). The median durations of prior exposure to protease inhibitors were 149Â weeks for patients receiving LEXIVA/ritonavir twice daily (49% received â‰¥2 prior protease inhibitors) and 130Â weeks for patients receiving lopinavir/ritonavir (40% received â‰¥2Â prior protease inhibitors).</p>
<p> The time-averaged changes in plasma HIV-1 RNA from baseline (AAUCMB) at 48Â weeks (the endpoint on which the study was powered) were -1.4Â log<span class="Sub">10</span>Â copies/mL for twice-daily LEXIVA/ritonavir and -1.67Â log<span class="Sub">10</span>Â copies/mL for the lopinavir/ritonavir group. </p>
<p> The proportions of patients who achieved and maintained confirmed HIV-1 RNA &lt;400Â copies/mL (secondary efficacy endpoint) were 58% with twice-daily LEXIVA/ritonavir and 61% with lopinavir/ritonavir (95% CI for the difference: -16.6, 10.1). The proportions of patients with HIV-1 RNA &lt;50Â copies/mL with twice-daily LEXIVA/ritonavir and with lopinavir/ritonavir were 46% and 50%, respectively (95% CI for the difference: -18.3, 8.9). The proportions of patients who were virologic failures were 29% with twice-daily LEXIVA/ritonavir and 27% with lopinavir/ritonavir.</p>
<p> The frequency of discontinuations due to adverse events and other reasons, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were similar between treatment arms.</p>
<p> Through 48Â weeks of therapy, the median increases from baseline in CD4+ cell counts were 81Â cells/mm<span class="Sup">3</span> with twice-daily LEXIVA/ritonavir and 91Â cells/mm<span class="Sup">3</span> with lopinavir/ritonavir. </p>
<p> This study was not large enough to reach a definitive conclusion that LEXIVA/ritonavir and lopinavir/ritonavir are clinically equivalent.</p>
<p> Once-daily administration of LEXIVA plus ritonavir is not recommended for protease inhibitor-experienced patients. Through WeekÂ 48, 50% and 37% of patients receiving LEXIVA 1,400Â mg plus ritonavir 200Â mg once daily had plasma HIV-1 RNA &lt;400Â copies/mL and &lt;50Â copies/mL, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92711343-d1bb-41e6-a3fb-0663c7bef756"></a><a name="section-13.6"></a><p></p>
<h2>
<span class="Bold">14.3</span> Pediatric Patients</h2>
<p class="First"> Two open-label studies in pediatric patients 2 to 18Â years of age were conducted. In one study, twice-daily dosing regimens (LEXIVA with or without ritonavir) were evaluated in combination with other antiretroviral agents. A second study evaluated once-daily dosing of LEXIVA with ritonavir; the data from this study were insufficient to support a once-daily dosing regimen in any pediatric patient population. </p>
<p> LEXIVA: Eighteen (16Â therapy-naive and 2Â therapy-experienced) pediatric patients received LEXIVA Oral Suspension without ritonavir twice daily. At Week 24, 67% (12/18) achieved HIV-1 RNA &lt;400Â copies/mL, and the median increase from baseline in CD4+ cell count was 353Â cells/mm<span class="Sup">3</span>.</p>
<p> LEXIVA plus ritonavir: Twenty-seven protease inhibitor-naive and 30Â protease inhibitor-experienced pediatric patients received LEXIVA Oral Suspension or Tablets with ritonavir twice daily. At Week 24, 70% of protease inhibitor-naive (19/27) and 57% of protease inhibitor-experienced (17/30) patients achieved HIV-1 RNA &lt;400Â copies/mL; median increases from baseline in CD4+ cell counts were 131Â cells/mm<span class="Sup">3</span> and 149Â cells/mm<span class="Sup">3</span> in protease inhibitor-naive and experienced patients, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_3a17c5da-ae43-4323-8b30-74a46887e53f"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"> LEXIVA Tablets, 700Â mg, are pink, film-coated, capsule-shaped, biconvex tablets, with â€œGXÂ LL7â€? debossed on one face. </p>
<p> Store at controlled room temperature of 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) (see USP Controlled Room Temperature). Keep container tightly closed.</p>
<p> LEXIVA Oral Suspension, a white to off-white grape-bubblegum-peppermint-flavored suspension, contains 50Â mg of fosamprenavir as fosamprenavir calcium equivalent to approximately 43Â mg of amprenavir in each 1Â mL.</p>
<p> This product does not require reconstitution. </p>
<p> Store at 5Â° to 30Â°C (41Â° to 86Â°F). Shake vigorously before using. Do not freeze.</p>
<p>This product is supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0281-1</td>
<td align="center">700 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">PINK</td>
<td align="center">0173-0721</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_0ebcad5c-0b40-4152-bf48-cf0e4a5a089c"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved Patient Labeling</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5cd9ba95-ab8d-4c73-81b1-d13a9b15b32d"></a><a name="section-15.1"></a><p></p>
<h2>
<span class="Bold">17.1</span> Drug Interactions</h2>
<p class="First">A statement to patients and healthcare providers is included on the product's bottle label: ALERT: Find out about medicines that should NOT be taken with LEXIVA. </p>
<p> LEXIVA may interact with many drugs; therefore, patients should be advised to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, particularly St. John's wort. </p>
<p> Patients receiving PDE5 inhibitors should be advised that they may be at an increased risk of PDE5 inhibitor-associated adverse events, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, visual changes, and <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, and should promptly report any symptoms to their healthcare provider. </p>
<p> Patients receiving hormonal contraceptives should be instructed to use alternate contraceptive measures during therapy with LEXIVA because hormonal levels may be altered, and if used in combination with LEXIVA and ritonavir, liver enzyme elevations may occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe223e40-7ee1-481d-82e2-05300d077cde"></a><a name="section-15.2"></a><p></p>
<h2>
<span class="Bold">17.2</span> Sulfa <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></h2>
<p class="First"> Patients should inform their healthcare provider if they have a sulfa <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>. The potential for cross-sensitivity between drugs in the sulfonamide class and fosamprenavir is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bec3b495-d4a4-42a7-b446-b0dba3c904dd"></a><a name="section-15.3"></a><p></p>
<h2>
<span class="Bold">17.3</span> Redistribution/Accumulation of Body Fat</h2>
<p class="First"> Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including LEXIVA, and that the cause and long-term health effects of these conditions are not known at this time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e7e613b6-b7a1-427b-8385-19c887e3af17"></a><a name="section-15.4"></a><p></p>
<h2>
<span class="Bold">17.4</span> Information About Therapy With LEXIVA</h2>
<p class="First"> Patients should be informed that LEXIVA is not a cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and that they may continue to develop <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> and other complications associated with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>. The long-term effects of LEXIVA are unknown at this time. Patients should be told that there are currently no data demonstrating that therapy with LEXIVA can reduce the risk of transmitting HIV to others.</p>
<p> Patients should be told that sustained decreases in plasma HIV-1 RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients should remain under the care of a physician while using LEXIVA. Patients should be advised to take LEXIVA every day as prescribed. LEXIVA must always be used in combination with other antiretroviral drugs. Patients should not alter the dose or discontinue therapy without consulting their physician. If a dose is missed, patients should take the dose as soon as possible and then return to their normal schedule. However, if a dose is skipped, the patient should not double the next dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_caa5fe0b-3c6c-4cfa-ae94-78df534af766"></a><a name="section-15.5"></a><p></p>
<h2>
<span class="Bold">17.5</span> Oral Suspension</h2>
<p class="First"> Patients should be instructed to shake the bottle vigorously before each use and that refrigeration of the oral suspension may improve the taste for some patients. </p>
<p>LEXIVA and AGENERASE are registered trademarks of GlaxoSmithKline.</p>
<p>GlaxoSmithKline Vertex Pharmaceuticals Incorporated</p>
<p>Research Triangle Park, NC 27709 Cambridge, MA 02139</p>
<p>Â©2009, GlaxoSmithKline. All rights reserved.</p>
<p>PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT</p>
<p>_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ </p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_c510ee46-8292-4b53-a4df-fda8467f581a"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">LEXIVA<span class="Sup">Â®</span></span></p>
<p>(lex-EE-vah)</p>
<p><span class="Bold">(fosamprenavir calcium) </span></p>
<p><span class="Bold">Tablets and Oral Suspension</span></p>
<p>Read the Patient Information that comes with LEXIVA before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. It is important to remain under a healthcare provider's care while taking LEXIVA. Do not change or stop treatment without first talking with your healthcare provider. Talk to your healthcare provider or pharmacist if you have any questions about LEXIVA.</p>
<p><span class="Underline"><span class="Bold">What is the most important information I should know about LEXIVA?</span></span></p>
<p>LEXIVA can cause dangerous and life-threatening interactions if taken with certain other medicines. Tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.</p>
<ul>
<li>Some medicines cannot be taken at all with LEXIVA.</li>
<li>Some medicines will require dose changes if taken with LEXIVA.</li>
<li>Some medicines will require close monitoring if you take them with LEXIVA.</li>
</ul>
<p>Know all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Keep a list of the medicines you take. Show this list to all your healthcare providers and pharmacists anytime you get a new medicine or refill. Your healthcare providers and pharmacists must know all the medicines you take. They will tell you if you can take other medicines with LEXIVA. Do not start any new medicines while you are taking LEXIVA without talking with your healthcare provider or pharmacist. You can ask your healthcare provider or pharmacist for a list of medicines that can interact with LEXIVA.</p>
<p><span class="Underline"><span class="Bold">What is LEXIVA?</span></span></p>
<p>LEXIVA is a medicine you take by mouth to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. HIV is the virus that causes AIDS (<span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immune deficiency syndrome</span>). LEXIVA belongs to a class of anti-HIV medicines called protease inhibitors. LEXIVA is always used with other anti-HIV medicines. When used in combination therapy, LEXIVA may help lower the amount of HIV found in your blood, raise CD4+ (T) cell counts, and keep your immune system as healthy as possible, so it can help fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. However, LEXIVA does not work in all patients with HIV. </p>
<p><span class="Bold">LEXIVA does not:</span></p>
<ul>
<li>cure <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> or AIDS. We do not know if LEXIVA will help you live longer or have fewer of the medical problems (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>) that people get with HIV or AIDS. <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic infections</span> are <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that develop because the immune system is weak. Some of these conditions are <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infections</span>, and <span class="Italics">Mycobacterium avium </span>complex (MAC) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. It is very important that you see your healthcare provider regularly while you are taking LEXIVA. The long-term effects of LEXIVA are not known.</li>
<li>lower the risk of passing HIV to other people through sexual contact, sharing needles, or being exposed to your blood. For your health and the health of others, it is important to always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood. Never use or share dirty needles.</li>
</ul>
<p>LEXIVA has not been fully studied in children under the age of 2 or in adults over the age of 65.</p>
<p><span class="Underline"><span class="Bold">Who should not take LEXIVA?</span></span></p>
<p><span class="Bold">Do not take LEXIVA if you:</span></p>
<ul>
<li>are taking certain other medicines. Read the sectionâ€œWhat is the most important information I should know about LEXIVA?â€? Do not take the following medicines<span class="Sup">*</span> with LEXIVA. You could develop serious or life-threatening problems. <ul>
<li>HALCIONÂ® (triazolam; used for <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) </li>
<li>Ergot medicines: dihydroergotamine, ergonovine, ergotamine, and methylergonovine such as CAFERGOTÂ®, MIGRANALÂ®, D.H.E. 45Â®, ergotrate maleate, METHERGINEÂ®, and others (used for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>)</li>
<li>PROPULSIDÂ® (cisapride), used for certain stomach problems</li>
<li>VERSEDÂ® (midazolam), used for sedation</li>
<li>ORAPÂ® (pimozide), used for Touretteâ€™s disorder</li>
</ul>
</li>
<li>are allergic to LEXIVA or any of its ingredients. The active ingredient is fosamprenavir calcium. See the end of this leaflet for a list of all the ingredients in LEXIVA.</li>
<li>are allergic to AGENERASE (amprenavir).<p class="First"></p>
<p></p>
</li>
</ul>
<p>You should not take AGENERASE (amprenavir) and LEXIVA at the same time.</p>
<p>There are other medicines you should not take if you are taking LEXIVA and NORVIRÂ® (ritonavir) together. You could develop serious or life-threatening problems. Tell your healthcare provider about all medicines you are taking before you begin taking LEXIVA and NORVIR (ritonavir) together.</p>
<p><span class="Underline"><span class="Bold">What should I tell my healthcare provider before taking LEXIVA?</span></span></p>
<p>Before taking LEXIVA, tell your healthcare provider about all of your medical conditions including if you: </p>
<ul>
<li>are pregnant or planning to become pregnant. It is not known if LEXIVA can harm your unborn baby. You and your healthcare provider will need to decide if LEXIVA is right for you. If you use LEXIVA while you are pregnant, talk to your healthcare provider about how you can be on the Antiretroviral Pregnancy Registry.</li>
<li>are breastfeeding. You should not breastfeed if you are HIV-positive because of the chance of passing the HIV virus to your baby through your milk. Also, it is not known if LEXIVA can pass into your breast milk and if it can harm your baby. If you are a woman who has or will have a baby, talk with your healthcare provider about the best way to feed your baby.</li>
<li>have liver problems. You may be given a lower dose of LEXIVA or LEXIVA may not be right for you.</li>
<li>have kidney problems</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. You may need dose changes in your insulin or other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines.</li>
<li>have <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span></li>
<li>are allergic to sulfa medicines</li>
</ul>
<p>Before taking LEXIVA, tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. LEXIVA can cause dangerous and life-threatening interactions if taken with certain other medicines. You may need dose changes in some of your medicines or closer monitoring with some medicines if you also take LEXIVA (see â€œWhat is the most important information I should know about LEXIVA.â€?). Know all the medicines that you take and keep a list of them with you to show healthcare providers and pharmacists.</p>
<p>Women who use birth control pills should choose a different kind of contraception. The use of LEXIVA with NORVIR (ritonavir) in combination with birth control pills may be harmful to your liver. The use of LEXIVA with or without NORVIR may decrease the effectiveness of birth control pills. Talk to your healthcare provider about choosing an effective contraceptive.</p>
<p><span class="Underline"><span class="Bold">How should I take LEXIVA?</span></span></p>
<ul>
<li>Take LEXIVA exactly as your healthcare provider prescribed.</li>
<li>Do not take more or less than your prescribed dose of LEXIVA at any one time. Do not change your dose or stop taking LEXIVA without talking with your healthcare provider.</li>
<li>You can take LEXIVA Tablets with or without food.</li>
<li>Adults should take LEXIVA Oral Suspension without food. </li>
<li>Pediatric patients should take LEXIVA Oral Suspension with food. If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurs within 30Â minutes after dosing, the dose should be repeated.</li>
<li>Shake LEXIVA Oral Suspension vigorously before each use.</li>
<li>When your supply of LEXIVA or other anti-HIV medicine starts to run low, get more from your healthcare provider or pharmacy. The amount of HIV virus in your blood may increase if one or more of the medicines are stopped, even for a short time.</li>
<li>Stay under the care of a healthcare provider while using LEXIVA.</li>
<li>It is important that you do not miss any doses. If you miss a dose of LEXIVA by more than 4Â hours, wait and take the next dose at the regular time. However, if you miss a dose by fewer than 4Â hours, take your missed dose right away. Then take your next dose at the regular time.</li>
<li>If you take too much LEXIVA, call your healthcare provider or poison control center right away.</li>
</ul>
<p><span class="Underline"><span class="Bold">What should I avoid while taking LEXIVA? </span></span></p>
<ul>
<li>Do not use certain medicines while you are taking LEXIVA. See â€œWhat is the most important information I should know about LEXIVA" and "Who should not take LEXIVA?â€?</li>
<li>Do not breastfeed. See â€œBefore taking LEXIVA, tell your healthcare providerâ€?. Talk with your healthcare provider about the best way to feed your baby.</li>
<li>Avoid doing things that can spread <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> since LEXIVA doesn't stop you from passing the <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> to others. </li>
<li>Do not share needles or other injection equipment.</li>
<li>Do not share personal items that can have blood or body fluids on them, like toothbrushes or razor blades.</li>
<li>Do not have any kind of sex without protection. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
<p><span class="Underline"><span class="Bold">What are the possible side effects of LEXIVA?</span></span></p>
<p>LEXIVA may cause the following side effects: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span>, some with <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, have happened in patients taking LEXIVA. <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of the face, lips, and tongue (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) has also been reported. Tell your healthcare provider if you get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or develop <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span> after starting LEXIVA.</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>). Some patients had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> before taking LEXIVA while others did not. Some patients may need changes in their <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine. Others may need a new <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine.</li>
<li>increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems in some patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>.</li>
<li>worse liver disease. Patients with liver problems, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C, are more likely to get worse liver disease when they take anti-HIV medicines like LEXIVA.</li>
<li>changes in blood tests. Some people have changes in blood tests while taking LEXIVA. These include increases seen in liver function tests and blood fat levels, and decreases in white blood cells. Your healthcare provider may do regular blood tests to see if LEXIVA is affecting your body.</li>
<li>changes in body fat. These changes have happened in patients taking antiretroviral medicines like LEXIVA. The changes may include an increased amount of fat in the upper back and neck ("<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>"), breast, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known at this time.</li>
<li><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span> have been reported in some patients taking LEXIVA. If you develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your side, blood in your urine, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> when you urinate) tell your healthcare provider right away.</li>
</ul>
<p>Common side effects of LEXIVA are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Tell your healthcare provider about any side effects that bother you or that won't go away. </p>
<p>This list of side effects of LEXIVA is not complete. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Underline"><span class="Bold">How should I store LEXIVA?</span></span></p>
<ul>
<li>LEXIVA Tablets should be stored at room temperature between 59Â° and 86Â°F (15Â° to 30Â°C). Keep the container of LEXIVA Tablets tightly closed.</li>
<li>LEXIVA Oral Suspension may be stored at room temperature or refrigerated. Refrigeration of LEXIVA Oral Suspension may improve taste for some patients. Do not freeze.</li>
<li>Keep LEXIVA and all medicines out of the reach of children.</li>
<li>Do not keep medicine that is out of date or that you no longer need. Be sure that if you throw any medicine away, it is out of the reach of children.</li>
</ul>
<p><span class="Underline"><span class="Bold">General information about LEXIVA</span></span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LEXIVA for a condition for which it was not prescribed. Do not give LEXIVA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about LEXIVA. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about LEXIVA that is written for health professionals. For more information you can call toll-free 888-825-5249 or visit www.LEXIVA.com.</p>
<p><span class="Underline"><span class="Bold">What are the ingredients in LEXIVA?</span></span></p>
<p>Tablets:</p>
<p>Active Ingredient: fosamprenavir calcium.</p>
<p>Inactive Ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and povidone K30. The tablet film-coating contains the inactive ingredients hypromellose, iron oxide red, titanium dioxide, and triacetin. </p>
<p>LEXIVA Tablets, 700Â mg, are pink in color and are capsule-shaped, with the letters â€œGXÂ LL7â€? printed on one side of the tablet.</p>
<div class="Figure"><img alt="Lexiva Tablet image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=009575f9-74e8-4a6d-9fa6-3cae72fd01c3&amp;name=26d3b057-5dd8-4bd5-8c05-2f9c28be35c4-03.jpg"></div>
<p>Oral Suspension:</p>
<p>Active Ingredient: fosamprenavir calcium</p>
<p>Inactive ingredients: artificial grape-bubblegum flavor, calcium chloride dihydrate, hypromellose, methylparaben, natural peppermint flavor, polysorbate 80, propylene glycol, propylparaben, purified water, and sucralose.</p>
<p>LEXIVA and AGENERASE are registered trademarks of GlaxoSmithKline.</p>
<p><span class="Sup">*</span> The brands listed are trademarks of their respective owners and are not trademarks of GlaxoSmithKline. The makers of these brands are not affiliated with and do not endorse GlaxoSmithKline or its products.</p>
<p>GlaxoSmithKline Vertex Pharmaceuticals Incorporated</p>
<p>Research Triangle Park, NC 27709 Cambridge, MA 02139</p>
<p>Â©2009, GlaxoSmithKline. All rights reserved.</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_04ed76ad-2f7c-4990-85d4-11c09dee759d"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Principal Display Panel</span></p>
<p>NDC 53808-0281-1 </p>
<p><span class="Italics">30 Tablets</span></p>
<p>LEXIVA<span class="Sup">Â® </span>(fosamprenavir calcium) TABLETS </p>
<p>700 mg</p>
<p>ALERT: Find out about medicines that should NOT be taken with LEXIVA.<br>R<span class="Sub">x</span> only</p>
<p>Note to Pharmacist: Do not cover ALERT box with pharmacy label.</p>
<p>For use in combination regimens with or without ritonavir.</p>
<p>Each tablet contains 700 mg of fosamprenavir as fosamprenavir calcium.</p>
<p>Store at controlled room temperature of 25ËšC (77ËšF); excursions permitted to 15Ëš to 30ËšC (59Ëš to 86ËšF) (see USP Controlled Room Temperature). </p>
<p>See package insert for Dosage and Administration.</p>
<p>LEXIVA is a trademark of GlaxoSmithKline.</p>
<p>Licensed from</p>
<p>VERTEX</p>
<p>Vertex Pharmaceuticals Incorporated</p>
<p>Cambridge, MA 02139</p>
<p>GlaxoSmithKline GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Made in England</p>
<div class="Figure"><img alt="Lexiva Tablet label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=009575f9-74e8-4a6d-9fa6-3cae72fd01c3&amp;name=Lexiva%20700mg(GlaxoSmithKline).jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEXIVAÂ 		
					</strong><br><span class="contentTableReg">fosamprenavir calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0281(NDC:0173-0721)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FOSAMPRENAVIR CALCIUM</strong> (AMPRENAVIR) </td>
<td class="formItem">FOSAMPRENAVIR CALCIUM</td>
<td class="formItem">700Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GX;LL7</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0281-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021548</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cece4944-71c2-4ded-a002-3475b1cae6a2</div>
<div>Set id: 009575f9-74e8-4a6d-9fa6-3cae72fd01c3</div>
<div>Version: 1</div>
<div>Effective Time: 20100414</div>
</div>
</div>Â <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
